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ABSTRACT 
 
INVESTIGATION OF METABOLISM AND MITOCHONDRIAL 
FUNCTION IN A DROSOPHILA MODEL OF FRAGILE X SYNDROME 
 
Eliana Danice Tarlow 
Thomas A. Jongens, PhD 
 
As early as 1943, reports first emerged of sex-linked transmission of intellectual 
disability. Several decades later, a cytogenetic variant found to segregate with intellectual 
impairment allowed for the localization and identification a pathogenic lesion in the 
fragile X mental retardation 1 (FMR1) gene. Subsequently, it was determined that loss-
of-function mutations in the FMR1 gene result in the aptly named Fragile X Syndrome 
(FXS). The landmark discovery of FXS etiology engendered a plethora of advances in the 
field of intellectual disability and autism. Notably, as the most common heritable form of 
intellectual disability and the leading monogenetic cause of autism, FXS is an ideal 
genetic paradigm for the study of the cellular and molecular underpinnings of the 
multifarious forms of intellectual impairment and autism. Moreover, the generation of 
animal models of FXS has greatly facilitated progress in the field. One such model, 
Drosophila melanogaster, is uniquely suited to rapid genetic and biochemical approaches 
to probe the processes and pathways involved in FXS pathogenesis. 
Recently, work from our laboratory implicated brain insulin signaling 
dysregulation in the development of behavioral and cognitive deficits in the Drosophila 
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model of FXS. This finding, along with reports that FXS patients with metabolic 
disturbances have a higher prevalence of clinically defined autism, prompted me to 
explore the metabolic implications of loss of FMR1 expression. In my thesis, I uncovered 
striking differences in metabolism in the Drosophila model of FXS. The metabolic 
alterations that I revealed provide clues about the biochemical pathways that are 
perturbed in FXS. Further, my efforts to elucidate the mechanism underlying the 
observed metabolic changes precipitated the exciting discovery of a novel, clinically 
relevant phenotype in feeding behavior. I also uncovered new evidence that aberrant 
mitochondrial function and morphology are involved in FXS pathophysiology. My 
findings provide a solid foundation for future dissection of the precise mechanistic links 
between metabolism, mitochondria, and behavioral and cognitive output in the context of 
FXS. 
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Graphical Abstract. Fragile X Syndrome (FXS) is caused by loss of FMR1 expression. 
While the implications of this pathogenic mutation are canonically considered in the 
context of the brain, in my thesis I elucidated clinically relevant systemic alterations in 
metabolism and mitochondrial function in a Drosophila model of FXS. 
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CHAPTER 1: 
 
 
INTRODUCTION1
																																								 																				
1 Portions of this Chapter have been excerpted with modification from a Review article; 
Weisz, E.D., Monyak, R.E., and Jongens, T.A. (2015). Deciphering discord: How 
Drosophila research has enhanced our understanding of the importance of FMRP in 
different spatial and temporal contexts. Exp. Neurol. 274, 14–24.	
2 
Summary 
Fragile X Syndrome (FXS) is the most common heritable form of intellectual 
impairment and the leading monogenetic cause of autism, with a prevalence of 1 in 4000 
males and 1 in 6000 females (Bardoni and Mandel, 2002; Bhogal and Jongens, 2010). In 
addition to its canonical definition as a neurodevelopmental disorder, recent findings in 
the clinic suggest that FXS has widespread systemic effects that include a variety of 
heterogeneous phenotypes. Efforts to study FXS pathogenesis have been aided by the 
development and characterization of animal models of the disease. While much remains 
unknown, it is increasingly apparent that FXS involves a myriad of spatial and temporally 
specific alterations in cellular function.  
In this Chapter, I will discuss the clinical features of FXS and highlight our 
current knowledge of the cellular and molecular underpinnings of FXS pathogenesis. I 
will review the generation and use of genetic models to approach questions in the FXS 
field with an emphasis on the Drosophila model system. Finally, I will examine 
discordant findings from these models of FXS and use the apparent dissonance as a lens 
to explore functions of the Drosophila Fragile X Mental Retardation Protein (dFMRP) in 
neuronal circuits, behavioral output pathways, and the response to cellular stress. 
  
3 
Clinical presentation of Fragile X Syndrome (FXS) 
 FXS pathophysiology is commonly characterized as a multifarious suite of 
behavioral, cognitive, and physical manifestations. Often, the first clinical indication of 
FXS is delayed attainment of developmental milestones (Garber et al., 2008). Males are 
typically more severely affected than females, as the FMR1 gene is located on the X 
chromosome (Hagerman et al., 2009; Kidd et al., 2014). Currently, the standard of care 
for determination of FXS is a DNA test. This genetic test enables clinicians to ascertain 
whether a proband has the most severe FMR1 mutation, termed the full mutation, and 
assess the level of methylation mosaicism (Boyle and Kaufmann, 2010). Given that the 
symptomology of FXS is so variable, it is essential that clinicians are aware of the wide 
range of phenotypes that are associated with FXS to ensure a prompt and proper 
diagnosis (Kidd et al., 2014). 
One of the archetypal neurobehavioral features of FXS is intellectual disability. 
Males with the full mutation present with mild (IQ 55-70) to moderate (IQ 40-54) 
intellectual impairment (Boyle and Kaufmann, 2010; Garber et al., 2008). Affected 
individuals experience cognitive challenges with working and short-term memory, 
language, and executive function (Boyle and Kaufmann, 2010). In addition to intellectual 
disability, it is estimated that approximately 30-60% of FXS patients have clinically 
defined autism (Boyle and Kaufmann, 2010; Hagerman et al., 2008). Autistic features 
observed in FXS patients include poor eye contact, excessive shyness, anxiety, 
aggression, hyperarousal in response to sensory stimuli, attention deficits, stereotypic 
movements such as hand flapping, and perseverative speech (Boyle and Kaufmann, 2010; 
Hagerman et al., 2008; O’Donnell and Warren, 2002). Moreover, affected individuals are 
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at an increased risk for seizures and many FXS patients have abnormal 
electroencephalographic findings, even in the absence of overt seizures (Hagerman et al., 
2009).  
 Despite these striking behavioral and cognitive features, brains taken at autopsy 
from FXS patients have no gross anatomical abnormalities (Garber et al., 2008; 
O’Donnell and Warren, 2002). Rather, postmortem examination revealed that the brains 
of affected individuals exhibit subtle changes in dendritic spine morphology (Irwin et al., 
2001). Specifically, FXS patients have increased long dendritic spines with immature 
morphology compared to age-matched control individuals. These characteristics suggest 
that there is a global failure in dendritic spine maturation and/or pruning in affected 
individuals (Irwin et al., 2001). Presumably, defects in dendritic spine morphology 
contribute to the behavioral and cognitive difficulties that FXS patients experience. 
While FXS is canonically defined as a neurodevelopmental disorder, several 
irregular physical features have also been observed in FXS patients (Kidd et al., 2014; 
O’Donnell and Warren, 2002). These phenotypes include altered facial structure, 
prominent ears, high-arched palate, and macro-orchidism in post-pubertal males 
(Jacquemont et al., 2007). Affected individuals also experience a spectrum of medical 
problems that are likely due to connective tissue dysplasia, such as velvet-like skin, 
finger-joint hyper-extensibility, recurrent otitis media, ocular disorders, gastrointestinal 
disturbances, and mitral valve prolapse (Kidd et al., 2014; O’Donnell and Warren, 2002). 
Clinicians must address these medical problems promptly, as they have the potential to 
exacerbate and/or increase the propensity for behavioral problems such as anxiety and 
aggression (Kidd et al., 2014). Awareness of these medical problems is particularly 
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critical when dealing with a nonverbal patients because they are often unable to articulate 
symptoms (Kidd et al., 2014). 
Moreover, reports in the clinical literature have suggested that individuals, 
particularly children, with FXS show signs of metabolic dysfunction. Children with FXS 
have been reported to have higher rates of obesity than the general population (Bailey et 
al., 2010; Raspa et al., 2010). Further, there have been several documented cases of 
affected individuals who exhibit hyperphagia and a lack of satiation after meals 
(Schrander-Stumpel et al., 2008; de Vries et al., 1993). This suite of symptoms has been 
termed the Prader-Willi Phenotype of FXS due to the substantial phenotypic similarity 
between the two conditions (Fryns et al., 1987; de Vries et al., 1993). These metabolic 
phenotypes appear to be particularly relevant on a behavioral and cognitive level, as 
affected individuals with these metabolic disturbances have more severe behavioral 
problems and a higher rate of autism than that typically seen in FXS patients (Hagerman 
et al., 2008; McLennan et al., 2011; Muzar et al., 2016; Nowicki et al., 2007). Despite 
these remarkable findings, there is a dearth of studies that assess metabolic function in 
FXS patients or animal models of the disease. 
 
Discovery of the fragile X mental retardation 1 (FMR1) gene 
 In 1943, Martin and Bell reported a pedigree that demonstrated the sex-linked 
transmission of intellectual disability (O’Donnell and Warren, 2002). Later, a cytogenetic 
variant with a characteristic constriction near the long arm of the X chromosome was 
found to segregate with intellectual impairment in a different family (Lubs, 1969). This 
site was subsequently localized to Xq27.3 and became known as the fragile X 
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chromosome (Harrison et al., 1983). The causal gene was cloned and identified in 1991 
as the fragile X mental retardation 1 (FMR1) gene (Verkerk et al., 1991).  
 Shortly thereafter, it was determined that FMR1 has two autosomal paralogs, 
termed fragile x related gene 1 and 2 (FXR1, FXR2) (Siomi et al., 1995; Zhang et al., 
1995). The products encoded by the FXR1 and FXR2 genes share 90% and 60% 
similarity with the product of FMR1, respectively (Siomi et al., 1995; Zhang et al., 1995). 
Moreover, all three members of the FMR protein family are capable of both homo- and 
hetero-dimerization (Siomi et al., 1995; Zhang et al., 1995). Currently, the extent to 
which the members of the FMR protein family have autonomous or overlapping 
functions remains unknown. To date, there have been no clinical reports of pathology or 
phenotypes associated with mutations in FXR1 or FXR2. Additionally, FXR1 and FXR2 
expression is normal in FXS patients (Bakker and Oostra, 2003; Siomi et al., 1995). 
  The FMR1 gene spans 38 kb and contains 17 exons (de Vries et al., 1998). There 
are 24 alternate splice forms of FMR1, although it is unknown whether each of these 
transcripts are functional (Pretto et al., 2015; de Vries et al., 1998). Consistent with the 
clinical presentation of FXS, while the protein encoded by the FMR1 gene is ubiquitously 
expressed, it is highly enriched in neurons and in testes (Abitbol et al., 1993; Devys et al., 
1993). 
 
Etiology of FXS  
 FXS is an X-linked dominant disorder that is almost exclusively caused by a non-
coding CGG trinucleotide repeat in the 5’ untranslated region (UTR) of the FMR1 gene 
(O’Donnell and Warren, 2002). In the typical population, the 5’ UTR of FMR1 is 
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polymorphic and contains between 6 and 60 CGG repeats (Figure 1.1) (O’Donnell and 
Warren, 2002). In contrast, over 200 CGG repeats are observed in patients with the full 
mutation (de Vries et al., 1998). This pathogenic expansion results in hypermethylation 
of the locus and subsequent transcriptional silencing of the FMR1 gene (Figure 1.1) 
(Oberlé et al., 1991; Sutcliffe et al., 1992; Verkerk et al., 1991). The remainder of FXS 
cases arise from rare atypical deletions or single point mutations within the coding region 
of the FMR1 gene (Bakker and Oostra, 2003).  
 Importantly, the severity of the phenotypes observed in FXS patients is often 
correlated with the magnitude of the loss of FMR1 expression (Hagerman et al., 2009). 
Affected males with favorable methylation and/or allele size mosaicism as well as 
affected females with a beneficially skewed X chromosome activation ratio generally 
have higher IQs and less prominent physical abnormalities (Hagerman et al., 2009). 
 
FMR1 premutation alleles 
 Alleles that contain between 60 and 200 CGG repeats in the 5’ UTR of FMR1 
have been named premutations (Figure 1.1) (O’Donnell and Warren, 2002). Unlike the 
full mutation, premutation alleles are unmethylated (Oostra and Willemsen, 2009). 
Importantly, due to their meiotic instability, premutations have the potential to expand 
and eventually become full mutations when transmitted maternally (Garber et al., 2008; 
Jacquemont et al., 2007; Oostra and Willemsen, 2009). 
 Carriers of premutation alleles are also at risk of developing a progressive 
neurodegenerative disorder called fragile X-associated tremor/ataxia syndrome (FXTAS) 
(Oostra and Willemsen, 2009). In contrast to the pathological loss of FMR1 expression 
seen in FXS, it appears that FXTAS results from a toxic elevation in the levels of FMR1 
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mRNA transcripts (Jacquemont et al., 2007). Moreover, female premutation carriers are 
more susceptible to premature ovarian insufficiency (POI) (Jacquemont et al., 2007). 
Notably, while FXS, FXTAS, and POI all involve repeat expansions in the 5’ UTR of the 
FMR1 gene, the clinical presentation and pathogenesis of each disorder is distinct. 
 
Fragile X Mental Retardation Protein (FMRP) is an RNA-Binding Protein 
 The protein product of the FMR1 locus is called Fragile X Mental Retardation 
Protein (FMRP). Many studies have demonstrated that FMRP functions as an RNA 
binding protein that is enriched in the nervous system (Ashley et al., 1993a; Brown et al., 
1998; Chen et al., 2003; Darnell et al., 2005; Siomi et al., 1993). Although its localization 
is primarily cytoplasmic, FMRP contains both nuclear localization and nuclear export 
signals (NLS and NES, respectively) (Figure 1.2) (Devys et al., 1993; Eberhart et al., 
1996; Verheij et al., 1993). These domains enable FMRP to shuttle between the nucleus 
and the cytoplasm (Ashley et al., 1993a; Tamanini et al., 1999). FMRP has been shown to 
associate with ribosomal precursor particles in the nucleolus as well as actively 
translating polyribosomes (Corbin et al., 1997; Khandjian et al., 1996; Willemsen et al., 
1996). In this way, the subcellular distribution of FMRP facilitates its cellular functions 
(Willemsen et al., 1996). 
In addition to the NLS and NES, FMRP also contains an RGG box and two 
heterogeneous nuclear RNP K homology domains (KH1 and KH2) (Figure 1.2)  (Siomi 
et al., 1993). These motifs allow for the recognition and preferential binding of specific 
higher-order RNA structures by FMRP (Brown et al., 2001). Specifically, the C-terminal 
RGG domain of FMRP associates with an intramolecular G quartet stem loop structure 
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and the KH2 domain has been shown to interact with a tertiary kissing complex (Darnell 
et al., 2001, 2005). The ability of FMRP to bind its mRNA targets is clinically relevant, 
as a deleterious mutation in the second KH domain was found to be the cause of a severe 
case of FXS (De Boulle et al., 1993). 
Consistent with the functional predictions that can be made based upon the 
aforementioned structural domains, FMRP can bind up to 4% of human fetal mRNA 
transcripts in vitro, including its own mRNA (Ashley et al., 1993a). Remarkably, it is 
estimated that FMRP binds to and regulates over 800 distinct mRNA targets in vivo 
(Darnell et al., 2011). From a functional standpoint, FMRP is primarily thought to act as 
a negative regulator of translation (Laggerbauer et al., 2001). However, FMRP has been 
shown to promote translation in some cases (Bechara et al., 2009; Krueger et al., 2011; 
Monzo et al., 2010). Additionally, FMRP participates in several other pathways that are 
known to modulate gene expression. For example, it has been shown that FMRP 
stabilizes and assists the transport of mRNAs within the cell (Dictenberg et al., 2008; 
Zalfa et al., 2007). It has also been found to interact with components of the RNA 
interference, small interfering RNA, and microRNA pathways (Caudy et al., 2002; 
Ishizuka et al., 2002; Jin et al., 2004). Taking the large number of putative mRNA targets 
along with evidence that FMRP is implicated in multiple aspects of gene regulation, it 
appears that while FXS is monogenic in nature, FMR1 has pleiotropic effects that likely 
underlie the diversity of phenotypes observed in FXS patients. 
  
10 
Animal models enhance our understanding of FXS pathogenesis 
 Advancements in genome sequencing technologies and their application to 
mapping the genomes of various species have illuminated the remarkable degree of 
conservation of genetic material across a broad spectrum of organisms. Paired with the 
ever-expanding repertoire of techniques used to manipulate genes and introduce disease-
causing mutations into an organism, this evolutionary conservation engenders the 
development of animal models that can be used as tools to ascertain the biological 
mechanisms involved in both the normal and aberrant functions of genes known to cause 
disease in humans. 
 Since the etiology of FXS is well characterized, researchers have been able to 
generate valuable animal models of the disease (Bakker and Oostra, 2003). These animal 
models are highly relevant on a translational level because they facilitate an increased 
understanding of FXS pathogenesis (Bakker and Oostra, 2003). Animal models are 
particularly advantageous because they allow researchers to control for genetic and 
environmental heterogeneity and thereby circumvent many of the limitations of human 
studies. 
 
Murine models of FXS 
 Efforts to generate an animal model of FXS began shortly after the human FMR1 
gene was cloned (Bakker and Oostra, 2003; Verkerk et al., 1991). Alignment of the 
predicted protein sequence of FMR1 with that of its murine ortholog, Fmr1, revealed a 
remarkable 97% amino acid identity (Ashley et al., 1993b). Further analysis 
demonstrated that the expression pattern of murine Fmr1 mRNA and protein resembles 
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that observed in human tissue (Hinds et al., 1993). Encouraged by these conserved 
molecular features, a murine model of FXS was generated in 1994 (Bakker et al., 1994). 
While the CGG trinucleotide repeat is present in the promoter region of Fmr1, the Fmr1-
knockout mouse (Fmr1 KO) was generated by the introduction of a homologous 
recombination targeting vector that disrupted the Fmr1 coding sequence (Bakker et al., 
1994). Fmr1 KO mice exhibit many phenotypes that mimic the clinical presentation of 
FXS. These phenotypes will be discussed in greater depth in the next section and are 
summarized in Table 1.1.  
 The Fmr1 KO mouse model is a valuable tool to study FXS pathogenesis, 
however, there are important caveats to consider when interpreting findings in this 
disease model. Notably, the expression of Fxr1 and Fxr2 is unaffected in Fmr1 KO mice 
(Bakker et al., 2000). Several lines of evidence from Fmr1/Fxr2 double-knockout mice 
suggest that Fmr1 and Fxr2 have redundant function with respect to circadian and 
metabolic phenotypes (Lumaban and Nelson, 2015; Zhang et al., 2008). However, the 
ability to tease apart the respective contribution of Fxr1 is hindered by the early postnatal 
death of Fxr1-knockout mice (Mientjes et al., 2004). Additionally, many of the 
phenotypes observed in Fmr1 KO mice are highly susceptible to genetic background. 
Comparisons of findings from different strains of Fmr1 KO mice indicate that 
phenotypes that are robust in one genetic background are often opposite or absent in other 
genetic backgrounds (Paradee et al., 1999; Pietropaolo et al., 2011). Given these 
limitations, it quickly became apparent that additional genetic models would be necessary 
to better understand FXS pathogenesis and elucidate potential routes for therapeutic 
intervention.  
12 
The Drosophila model of FXS 
 With the advent of a wealth of genetic tools, Drosophila melanogaster has 
emerged as a highly tractable model for the study of FXS (Dockendorff et al., 2002; 
Inoue et al., 2002; Morales et al., 2002; Zhang et al., 2001). The Drosophila genome 
encodes a single gene, dfmr1, that is the sole fly ortholog of all three members of the 
FMR protein family (Wan et al., 2000). Importantly, the product of  the dfmr1 gene, 
termed dFMRP, shares both sequence identity and biochemical properties with those of 
its mammalian ortholog (Figure 1.2) (Wan et al., 2000). Much like its mammalian 
counterpart, dFMRP is an RNA-binding protein that has been shown to bind to select 
mRNA transcripts and repress their translation (Reeve et al., 2005; Zhang et al., 2001). 
Moreover, it has been demonstrated that the RNA-binding affinity of dFMRP is highly 
conserved, which suggests that the RNA-binding profile of dFMRP greatly resembles the 
list of mRNA targets bound by FMRP (Brown et al., 2001; Darnell et al., 2009, 2011; 
Miyashiro et al., 2003). While only a handful of mRNA targets of dFMRP have been 
identified in Drosophila, the targets that have been validated encode proteins that 
function in cytoskeleton maintenance and larval crawling behavior (Lee et al., 2003; 
Reeve et al., 2005; Xu et al., 2004; Zhang et al., 2001). Notably, the products of these 
mRNA targets have functional properties that are very similar to those identified in the 
murine model of FXS (Castets et al., 2005; Lu et al., 2004).  
 In addition to these genetic and functional similarities, flies that harbor loss-of-
function mutations in the dfmr1 gene recapitulate many of the characteristics of FXS 
(Table 1.1). Specifically, dfmr1 mutant flies show defects in memory, social behavior, 
circadian rhythmicity, and sleep (Bolduc et al., 2008; Bushey et al., 2009; Dockendorff et 
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al., 2002; Inoue et al., 2002; McBride et al., 2005; Morales et al., 2002). Further, dfmr1 
mutant flies exhibit defects in neural architecture that are reminiscent of the dendritic 
spine defects seen in both human patients and murine models of FXS (Comery et al., 
1997; Dockendorff et al., 2002; Lee et al., 2003; Michel et al., 2004; Morales et al., 2002; 
Zhang et al., 2001). These robust correlates to mammalian phenotypes render the 
Drosophila model an ideal paradigm to study the cellular and molecular mechanisms 
involved in FXS pathogenesis and to ascertain the efficacy of novel therapeutic 
approaches. 
 
Diverse functions of dFMRP in different spatiotemporal contexts 
Recent work in the Drosophila model of FXS suggests that dFMRP plays an 
important role in the modulation of intracellular processes that are important for cellular 
stability and maintenance. Multiple lines of evidence suggest that dFMRP acts in a highly 
cell type-, temporal-, and pathway-specific manner. These findings, coupled with 
observations in murine models of FXS, provide a compelling case that future progress 
depends upon increased understanding of the spatiotemporal requirements for FMRP. 
 
Neuronal Circuits: 
Neural Stem Cells 
The process of neurogenesis is critical for proper assembly of neural circuitry and 
the establishment of accurate brain connectivity. This intricate, highly orchestrated 
process is driven by the proliferation of stem cells and progenitor cells, which 
subsequently differentiate into neurons and glia. It is essential to achieve the correct 
14 
balance between neurons and glia, as an incorrect ratio of neurons to glia promotes 
aberrant wiring of the brain. Importantly, Drosophila neuroblasts (NBs) follow general 
stem cell principles and employ conserved molecular pathways (Callan and Zarnescu, 
2011; Callan et al., 2010). As such, NBs have emerged as a valuable model to study stem 
cell proliferation and differentiation during development. Callan et al., utilized the wealth 
of genetic tools available in Drosophila to elucidate the role of dFMRP during early 
neurogenesis in vivo (Callan et al., 2010). The results of their loss-of-function studies and 
clonal analyses in larval NBs suggest that dFMRP is required during early stages of 
development before synaptogenesis occurs. Loss of dFMRP was found to increase the 
proliferative capacity of larval NBs and promote the generation of supernumerary 
neurons that survive into adulthood. Moreover, these studies revealed that larval NBs 
lacking dFMRP exit quiescence prematurely and proliferate sooner than their wild-type 
counterparts. However, this enhanced early proliferation is followed by a deceleration of 
proliferation later in development. This important discovery provided the first evidence 
that dFMRP modulates proliferation in larval NBs by regulating the time at which neural 
progenitors exit quiescence. In a subsequent publication, Callan et al., expanded upon 
these findings and utilized tissue-specific RNA interference to elucidate the 
spatiotemporal role of dFMRP during larval brain development (Callan et al., 2012). 
Their observations suggest that there is heterogeneity in the temporal requirement for 
dFMRP such that dFMRP regulation is required during distinct developmental windows 
in different cell types. Specifically, dFMRP appears to be required first in NBs and 
subsequently in glia to control exit from quiescence (Callan et al., 2012). Importantly, 
this is the first study to assert that dFMRP functions to regulate NB reactivation in glial 
15 
cells in vivo. To address the mechanism by which dFMRP regulates the timing of NB 
reactivation, Callan et al., monitored components of the insulin signaling pathway, as this 
pathway has been shown to modulate neurogenesis (Callan et al., 2012; Chell and Brand, 
2010; Sousa-Nunes et al., 2011). Callan et al., showed that elevations of pAkt in the 
larval brain are concurrent with the developmental window during which dFMRP is 
required in glial cells (Callan et al., 2012). They also demonstrated that dfmr1 genetically 
interacts with dFoxO, a key transcriptional regulator of insulin signaling (Callan et al., 
2012). Together, these results suggest that the interplay between dFMRP and the insulin 
signaling pathway modulates NB reactivation in vivo. The complexity of the results from 
these Drosophila studies provide strong evidence that dFMRP plays distinct, cell type-
specific roles during different developmental time points in vivo. This conclusion 
emphasizes the need for members of the field to be cognizant of the spatial and temporal 
context in which studies are conducted to gain a better understanding of the molecular 
underpinnings of FXS pathology. 
 Consistent with observations in Drosophila, studies in mice have shown that 
FMRP regulates the timing and proliferation of neural stem and progenitor cells and that 
it is required to generate appropriate numbers of neurons and glia (Guo et al., 2011; Luo 
et al., 2010; Saffary and Xie, 2011). Much like Drosophila larval NBs, one such study 
used a combination of in vitro and in vivo approaches to assess the effect of FMRP 
deficiency on adult neurogenesis in the mammalian hippocampus (Luo et al., 2010). The 
results from experiments conducted in cultured explants of mouse adult neural progenitor 
cells (aNPCs) and in vivo monitoring of endogenous mouse aNPCs suggest that 
proliferation is augmented in Fmr1 KO aNPCs (Luo et al., 2010). Moreover, loss of 
16 
FMRP alters aNPC fate specification such that Fmr1 KO aNPCs exhibit decreased 
neuronal differentiation and increased glial differentiation (Luo et al., 2010). Additional 
experiments revealed that FMRP regulates the expression of proteins involved in cell 
cycle progression as well as GSK3β, a key component of the Wnt signaling pathway 
(Luo et al., 2010). Based on these and other mechanistic findings, Luo et al., hypothesize 
that Fmr1 deficiency results in dysregulation of the Wnt signaling pathway and thereby 
alters the proliferative capacity and fate specification of mouse aNPCs (Luo et al., 2010). 
Moreover, loss-of-function studies in the neocortex of mouse embryos suggest that 
FMRP suppresses the transition from stem-cell like radial glial cells (RGCs) to 
intermediate progenitor cells (IPCs) in a time dependent manner (Saffary and Xie, 2011). 
This result is consistent with the observation that dFMRP is important in the early stages 
of neurogenesis in Drosophila (Callan et al., 2010). However, the results in Luo et al., 
indicate that loss of Fmr1 depletes the population of RGCs, which is the opposite of what 
is seen in Drosophila larval NBs and mouse aNPCs (Callan et al., 2010; Luo et al., 2010). 
This discrepancy is likely due to differences in neural stem cell proliferation in different 
tissues at different times. 
From a behavioral standpoint, ablation of FMRP and the consequent alterations in 
hippocampal neurogenesis result in impaired performance in two different hippocampus-
dependent learning paradigms. However, selective restoration of FMRP in adult neural 
stem cells (aNSCs) rescues the cellular and behavioral phenotypes that occur in Fmr1 KO 
mice (Guo et al., 2011). It is possible that GSK3β hyperactivity modulates these 
phenotypes, as pharmacological treatment with a highly specific GSK3β inhibitor 
ameliorates aberrant cell fate specification, enhances the integration of newborn neurons 
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into circuits, and rescues impairments in hippocampus-dependent learning in Fmr1 KO 
mice (Guo et al., 2012). 
 Despite the differences inherent to each model system, it is clear that findings in 
the literature converge on a common notion that the role of FMRP in neurogenesis is 
diverse and tightly regulated at different time points and in different cellular populations. 
There appears to be a shared theme of overproliferation and differentiation defects in 
neural stem and progenitor cells in the absence of FMRP (Callan et al., 2010; Guo et al., 
2011; Luo et al., 2010; Saffary and Xie, 2011). The observation that FMRP regulates 
neurogenesis in aNPCs by controlling the production of neurons and glia underscores the 
important role that FMRP plays in the establishment of proper neural circuitry and 
accurate connectivity. The findings by Guo et al., that loss of FMRP in aNPCs results in 
learning deficits that can be rescued by restoration of FMRP in this cell population 
provide further support for the hypothesis that loss of FMRP can result in aberrant 
connections that are detrimental to behavioral and cognitive output (Guo et al., 2011). 
From a therapeutic perspective, recent findings in Drosophila and mice have uncovered 
novel targets that have the potential to benefit patients and have identified critical time 
points during which intervention might be most efficacious.  
 
Cytoskeleton and neural architecture 
 FMRP plays an important role in the establishment and maintenance of 
intracellular microtubule and actin scaffolds.  Previous reports have demonstrated that 
FMRP represses the translation of microtubule associated protein 1B (MAP1B) in both 
flies and mice (Lu et al., 2004; Zhang et al., 2001). Additionally, FMRP has been shown 
18 
to associate with components of kinesin and dynein to regulate mRNA trafficking along 
microtubules (Dictenberg et al., 2008; Estes et al., 2008; Ling et al., 2004). More 
recently, dfmr1 was shown to genetically interact with the spastin gene, which encodes a 
microtubule severing protein (Yao et al., 2011). Under normal conditions, spastin 
promotes the proper assembly of neuronal microtubules to ensure appropriate synaptic 
growth (Trotta et al., 2004). The interaction between dfmr1 and spastin is essential 
because it enables migration of mitochondria along microtubules (Yao et al., 2011). 
Outside of the nervous system, dFMRP facilitates the organization of microtubules in 
peripheral tissues. As such, loss of dfmr1 expression in the germline alters the 
configuration of microtubules in spermatozoa and likely contributes to the infertility 
observed in dfmr1 mutant males (Zhang et al., 2004).  
 Analogous to what is observed in the case of microtubule organization, normal 
dfmr1 expression is also critical for maintenance of the actin cytoskeleton.  It has long 
been known that dFMRP binds to and represses the translation of chickadee, which is the 
Drosophila ortholog of profilin (Reeve et al., 2005). This finding is particularly 
intriguing because the protein encoded by chickadee binds to actin. In a recent study, 
dfmr1 was also shown to interact with cheerio, the Drosophila ortholog of filamin A  
(Bolduc et al., 2010a).  Since cheerio is important for remodeling of the actin 
cytoskeleton, the results from the studies conducted by Reeve et al., and Bolduc et al., 
suggest that actin dynamics are altered in dfmr1 mutant flies (Bolduc et al., 2010a; Reeve 
et al., 2005). These molecular changes in actin dynamics appear to affect behavior and 
cognition, as flies that are heterozygous for loss-of-function mutations in cheerio and 
dfmr1 have impaired olfactory long-term memory (Bolduc et al., 2010a). To complement 
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this behavioral data, Bolduc et al., present molecular evidence that cheerio expression is 
lower in dfmr1 mutant flies than in wild-type counterparts after training in a memory 
paradigm (Bolduc et al., 2010a).  The observed changes in the maintenance of the actin 
cytoskeleton in the Drosophila model of FXS are also present in murine models of the 
disease, as Fmr1 KO mice exhibit impaired phosphorylation of p-21-activated kinase 
(PAK) and subsequent delayed stabilization of newly formed actin filaments in response 
to theta burst afferent stimulation (Chen et al., 2010). These results are relevant from a 
therapeutic standpoint because genetic and pharmacological inhibition of PAK has been 
shown to mitigate audiogenic seizures and hyperactivity in Fmr1 KO mice (Dolan et al., 
2013; Hayashi et al., 2007).  Together, these discoveries suggest that improper regulation 
of the actin cytoskeleton is likely one mechanism by which the absence of FMRP results 
in aberrant behavior and cognition.  
Along with cytoskeletal defects, dfmr1 mutant flies also have aberrations in neural 
architecture. In the central nervous system (CNS), overelaborated branching has been 
observed in the small ventral lateral neurons (sLNvs), which constitute the component of 
the central circadian clock that drives circadian rhythms in free-running conditions in 
Drosophila (Dockendorff et al., 2002; Gatto and Broadie, 2009; Morales et al., 2002). 
Additionally, the architecture of the Mushroom Bodies (MBs), which constitute the 
primary learning and memory center of the fly brain, cross over the midline and exhibit 
varying levels of fusion in the dfmr1 mutants (Michel et al., 2004; Reeve et al., 2005).  
 To expand upon these behavioral and neuroanatomical findings, subsequent 
studies utilized a variety of genetic and pharmacological manipulations to demonstrate 
that inhibition of matrix metalloproteinase (MMP), an enzyme that is important for 
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remodeling of the extracellular matrix, rescues the observed morphological defects in the 
sLNvs and MBs (Siller and Broadie, 2011). Since dfmr1 mutant flies also exhibit 
architectural defects in the neuromuscular junction (NMJ) (Zhang et al., 2001), Siller and 
Broadie expanded upon their findings in the CNS and examined the effect of treatment 
with minocycline, an MMP inhibitor, on peripheral motor structural changes. While this 
manipulation did ameliorate structural alterations in NMJs, the NMJ phenotype was less 
sensitive to minocycline dosage than the alterations in the CNS. Together these results 
indicate that central and peripheral neurons respond differently to drug treatment (Siller 
and Broadie, 2011). Similarly, studies in Fmr1 KO mice indicate that mmp9 mRNA co-
localizes with FMRP both at the synapse and in dendrites (Janusz et al., 2013). The 
observed co-localization likely has functional relevance, as treatment with minocycline or 
genetic reduction of MMP9 rescues dendritic spine defects and aberrant behavior in Fmr1 
KO mice (Bilousova et al., 2009; Sidhu et al., 2014). Compellingly, FXS patients that 
were treated with minocycline showed some improvements in both mood and anxiety. 
This finding indicates that the positive effects of minocycline observed in Drosophila and 
mouse models may translate to the clinic (Leigh et al., 2013; Paribello et al., 2010). 
 Clearly the study of disruptions in the neural architecture of the sLNvs, MBs, and 
NMJs has yielded promising insight into the ways in which the loss of dFMRP affects 
neuronal morphology. However, the role of dFMRP extends beyond regulation of neural 
branching. Specifically, a novel phenotype has been identified in a subset of the pigment 
dispersing factor (PDF)-positive neurons located in the tritocerebrum, known as the PDF-
TRI cells. While these neurons normally undergo apoptosis within two days of eclosion 
(Renn et al., 1999), experimental results indicate that the PDF-TRI cells fail to properly 
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undergo apoptosis in dfmr1 mutant flies (Gatto and Broadie, 2011). Further, another class 
of neurons entitled the crustacean cardioactive peptide (CCAP) peptidergic neurons 
exhibit delayed clearance in dfmr1 mutant flies (Gatto and Broadie, 2011). Thus, these 
findings highlight a critical role for dFMRP in the spatiotemporal regulation of apoptosis 
in the CNS. Although the functional implications of the ectopic persistence of these 
neurons are yet to be determined, these findings highlight another mechanism by which 
loss of dFMRP disrupts neural architecture. These results suggest that further exploration 
of the mechanism by which FMRP influences synaptic architecture and the resultant 
functional consequences that occur in the absence of FMRP may reveal promising, novel 
targets for therapeutic intervention. 
 
Inhibitory Circuit  
At the circuit level, multiple studies have shown that the excitatory/inhibitory 
(E/I) balance is perturbed in FXS neuronal networks (Cea-Del Rio and Huntsman, 2014; 
Doll and Broadie, 2014; Gatto and Broadie, 2010). Since the correct E/I balance is 
critical for proper maintenance of neuronal networks, several groups have postulated that 
E/I imbalance in the circuitry of CNS might underlie many of the observed deficits in 
FXS. Recent work in the Drosophila model system has broadened our understanding of 
how inhibitory and excitatory neural circuits contribute to FXS disease pathogenesis. 
 One factor that has been implicated in circuit dysfunction in FXS is altered 
inhibitory GABAergic neurotransmission (Cea-Del Rio and Huntsman, 2014; Doll and 
Broadie, 2014; Paluszkiewicz et al., 2011). While the theory that hypoinhibiton is a 
causal factor in FXS has garnered much appreciation, the field has been stymied by 
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seemingly contradictory results regarding alterations observed in GABAergic signaling in 
animal models of FXS. Fortunately, recent advances in Drosophila genetics have 
rendered the fly model of FXS a particularly useful tool to assay GABAergic circuitry. 
Drosophila researchers pioneered the notion that GABA has therapeutic potential for 
FXS following the result of a high throughput chemical screen to identify compounds 
that rescued excess dietary glutamate-induced lethality in dfmr1 mutant flies (Chang et 
al., 2008). Strikingly, in addition to preventing lethality, pharmacological treatment with 
GABA or GABA reuptake inhibitors was able to rescue neuroanatomical defects, excess 
futsch translation, and abnormal naïve courtship behavior in dfmr1 mutant flies (Chang et 
al., 2008). Despite these promising initial observations, recent research suggests that 
pharmacological augmentation of GABAergic signaling alone is not sufficient to restore 
MB-dependent olfactory learning deficits (Gatto et al., 2014). Close examination of 
GABAergic circuitry in the MB identified several molecular changes that arise in the 
absence of dFMRP (Gatto et al., 2014). Specifically, the dfmr1 mutant flies have reduced 
expression of GABAA receptor subunits as well as decreased levels of the rate-limiting 
enzyme involved in GABA synthesis, glutamic acid decarboxylase (GAD) (Gatto et al., 
2014). From a functional standpoint, Gatto et al., found that calcium signaling and 
kinetics in response to acute depolarization are altered in the inhibitory neurons of the 
MB in dfmr1 mutant flies (Gatto et al., 2014). Moreover, the GABAergic neurons that 
innervate the MB cells exhibit aberrant architectural development (Gatto et al., 2014). 
Interestingly, the developmental trajectory of these neurons is defined by 
underdevelopment at earlier stages that is subsequently followed by overelaboration. 
Gatto et al., noted that they observe undergrowth in these inhibitory MB cells at the same 
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time that overgrowth has been reported in excitatory MB cells (Gatto et al., 2014; Siller 
and Broadie, 2011). Based on this contrast, Gatto et al., postulate that dFMRP may play 
different roles in inhibitory versus excitatory MB cell populations (Gatto et al., 2014). 
This possibility suggests that dFMRP function is exquisitely cell-type specific. 
The notion that GABAergic circuit function in the CNS may not be uniform has 
also been noted in murine models of FXS. At the molecular level, there appear to be brain 
region specific alterations in the levels of GABA receptor subunits as well as in enzymes 
involved in GABA synthesis, transport, and catabolism in Fmr1 KO mice (Adusei et al., 
2010; D’Hulst et al., 2009; El Idrissi et al., 2005; Olmos-Serrano et al., 2010; 
Paluszkiewicz et al., 2011). These changes include an apparent decrease in the levels of 
GAD and vesicular GABA in the amygdala of Fmr1 KO mice (Olmos-Serrano et al., 
2010). In contrast, increases in the levels of GAD and the β-subunit of the GABA 
receptor have been observed in the cortex, hippocampus, brainstem, and diencephalon of 
Fmr1 KO mice (El Idrissi et al., 2005). In addition to these regional differences, GABAA 
receptor subunits and GABA enzymes demonstrate extremely dynamic and complex 
changes in their expression profiles at different times during development in Fmr1 KO 
mice (Adusei et al., 2010). From a behavioral standpoint, treatment with GABAA 
receptor agonists has been shown to decrease the incidence of audiogenic seizures in 
Fmr1 KO mice (Darnell and Klann, 2013; Heulens et al., 2012). Similarly, treatment with 
arbaclofen, a GABAB receptor agonist, was shown to correct exaggerated protein 
synthesis, reduce susceptibility to audiogenic seizures, and normalize repetitive behavior 
in the murine model of FXS (Darnell and Klann, 2013; Henderson et al., 2012). 
However, it has been shown that while pharmacological administration of a GABAA 
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receptor agonist ameliorates excitability deficits in the amygdala, hyperactivity, and 
deficits in pre-pulse inhibition, this manipulation exacerbates cued fear and startle 
responses (Olmos-Serrano et al., 2011). Given these findings it appears that from a 
therapeutic perspective GABA receptor agonists are potentially advantageous in some 
contexts, but that they are by no means a panacea. Additional studies must be conducted 
to ascertain the precise spatiotemporal role of FMRP in GABAergic circuitry in order to 
identify whether this is a viable intervention strategy and, if so, which patients are the 
best candidates for treatment with these compounds. 
 
Excitatory Circuit 
Much like the extensive literature on inhibitory circuits, it is widely appreciated 
that FMRP is important in excitatory circuits. It is primarily thought that FMRP 
modulates excitatory circuits through its relationship with metabotropic glutamate 
receptors (mGluRs). A prevalent hypothesis in the field suggests that the mGluR pathway 
is hyperactive in FXS (Bear et al., 2004). Consistent with this theory, it has been shown 
that inhibition of the mGluR pathway rescues behavioral and anatomical phenotypes in 
both fly and mouse models of FXS (Dolen et al., 2007; McBride et al., 2005; Michalon et 
al., 2012; Yan et al., 2005).  
Lately, the focus of the field has shifted towards the study of several other 
signaling pathways that are dysregulated in FXS. Many recent studies have sought to 
assess the interplay between these pathways, particularly the way in which molecules that 
participate in multiple signaling pathways contribute to the observed behavioral and 
cognitive deficits. One such study in the Drosophila model of FXS indicates that while 
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mGluR antagonists rescue an age-onset defect in a social learning paradigm, this deficit 
was also rescued by lithium, a known direct and indirect inhibitor of Glycogen Synthase 
Kinase-3 (GSK-3) (Choi et al., 2010). Lithium was previously identified as a compound 
of interest when it was shown to rescue short-term memory deficits in dfmr1 mutant flies 
(McBride et al., 2005). Subsequent studies in murine models of FXS provided additional 
evidence that GSK-3 is hyperactive in the disease state and suggested that the observed 
dysregulation of GSK-3 is likely caused by decreased levels of inhibitory 
phosphorylation at a conserved residue (Yuskaitis et al., 2010). A recent study that 
probed the interaction between the mGluR pathway and the GSK-3 pathway found that 
inhibition of mGluR5 resulted in increased inhibitory phosphorylation of GSK-3  
(Yuskaitis et al., 2010). This finding suggests that the observed excess in glutamatergic 
signaling might be linked to GSK-3 hyperactivity. Notably, another group found that 
treatment of Fmr1 KO mice with highly specific pharmacological inhibitors of GSK-3 
normalized multiple phenotypes that appear to be resistant to pharmacological inhibition 
of the mGluR pathway (Franklin et al., 2014). The dichotomy between the observations 
in Yuskaitis et al., and Franklin et al., indicates that the mGluR and GSK-3 pathways 
collaborate in some, but not all situations to promote normal behavior (Franklin et al., 
2014; Yuskaitis et al., 2010).  
 The field must remain cognizant that mGluR inhibitors do not rescue all of the 
phenotypes observed in animal models of FXS. Studies in dfmr1 mutant flies suggest that 
pharmacological treatment with mGluR inhibitors does not ameliorate irregular grooming 
patterns, arrhythmic circadian behavior, and increased sleep (Bushey et al., 2009; 
McBride et al., 2005; Tauber et al., 2011). Similarly, it has been shown that inhibition of 
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the mGluR pathway does not rescue macro-orchidism in the murine model of FXS 
(Dolen et al., 2007). Taken together, these results indicate that while increased activity of 
the mGluR pathway is involved in FXS pathophysiology, FXS is not solely a product of 
mGluR hyperactivation. Instead, the dysregulation of and complex interactions between 
multiple signaling pathways underlie FXS pathogenesis. 
 
Peripheral Motor Output Pathways 
While much emphasis has been placed on understanding the role of FMRP in the 
CNS, many studies have demonstrated that FMRP is also important in peripheral motor 
output pathways. In Drosophila, the larval NMJ has been established as a highly 
tractable, well-defined system for the study of synaptic structure and function in a 
peripheral motor context. It is widely appreciated that loss of dFMRP results in robust 
NMJ phenotypes including synaptic overgrowth and altered neurotransmission (Zhang et 
al., 2001). However, the precise mechanistic underpinnings of these defects remain 
largely unknown. Recently, research in dfmr1 mutant flies has greatly expanded our 
understanding of how dFMRP involvement in post-transcriptional gene regulation as well 
as in cascades that govern trans-synaptic signaling is critical for the establishment and 
maintenance of proper synaptic structure and function. 
In addition to its predicted function as a translational regulator, FMRP has also 
been shown to modulate other aspects of RNA biology (Bhogal et al., 2011; Xu et al., 
2013). An elegant series of biochemical and genetic experiments revealed that dFMRP 
acts in the RNA editing system to regulate synaptic architecture (Bhogal et al., 2011). 
Specifically, Bhogal et al., demonstrated that dFMRP and Drosophila adenosine 
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deaminase acting on RNA (dADAR) biochemically interact (Bhogal et al., 2011). To 
probe the physiological relevance of this interaction in vivo, genetic epistasis experiments 
were conducted in flies with loss-of-function mutations in both dfmr1 and dAdar (Bhogal 
et al., 2011). Since the phenotypes associated with each single mutant are distinct, 
analysis of double mutant flies allowed Bhogal et al., to ascertain that dFMRP acts 
upstream of dADAR in a common pathway responsible for the establishment of NMJ 
morphology (Bhogal et al., 2011). Examination of editing in several candidate transcripts 
revealed that RNA editing was in fact altered in dfmr1 mutant flies, indicating that the 
interaction between dFMRP and dADAR has functional consequences (Bhogal et al., 
2011). Further work will be necessary to determine if RNA editing is similarly affected in 
Fmr1 KO mice and human patients (Bassell, 2011). Importantly, this study was the first 
to identify an interaction between a disease-associated protein and a protein involved in 
Adenosine-to-Inosine RNA editing. 
Similarly, dFMRP has been shown to biochemically and genetically interact with 
Drosophila topoisomerase 3β (dTop3β) and Drosophila Tudor domain-containing protein 
3 (dTDRD3) in a complex that is conserved in mammals (Xu et al., 2013). Like dFMRP, 
both dTop3β and dTDRD3 associate with mRNA (Linder et al., 2008; Xu et al., 2013). 
To evaluate the function of the resultant protein complex in vivo, Xu et al., examined 
phenotypes generated in the Drosophila eye and NMJ in response to manipulation of the 
corresponding genes (Xu et al., 2013). Based on the results of genetic epistasis 
experiments, Xu et al., concluded that dTop3β and dfmr1 functionally antagonize each 
other to regulate eye development and NMJ formation (Xu et al., 2013). Notably, this 
result is reminiscent of the genetic interaction that Bhogal et al., observed between dfmr1 
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and dAdar (Bhogal et al., 2011). In contrast, the other member of this complex, dTDRD3, 
appeared to have a positive effect on dFMRP function in the Drosophila eye (Xu et al., 
2013). The opposing roles that dTop3β and dTDRD3 play with respect to eye 
development suggest that these proteins may have an antagonistic relationship in this 
context. Together, these findings reveal that the interaction between dFMRP, dTop3β, 
and dTDRD3 is incredibly cell-type specific. In addition to cell-type specificity, Xu et 
al., demonstrated that the functional relationship between dFMRP and dTop3β is distinct 
at the level of gene regulation (Xu et al., 2013). Contrary to the observed negative 
interaction between dFMRP and dTop3β in eye development and overall NMJ 
architecture, these proteins were show to operate coordinately to promote the expression 
of a common target, ptk2, in NMJs (Xu et al., 2013). As such, it is possible that dFMRP 
may antagonize dTop3β function on certain mRNAs and facilitate its action on other 
mRNAs to regulate gene expression at the synapse. To further illustrate the importance of 
Top3β in synapse formation, Xu et al., cultured and stained primary cortical neurons 
from Top3β KO mice and showed that synapse formation is altered in these animals (Xu 
et al., 2013). The discovery of these novel roles for FMRP in synaptogenesis greatly 
expands our understanding of FMRP function. However, the evidence for seemingly 
contradictory functions of FMRP in different contexts leaves the field with more 
questions than answers. It has become increasingly evident that the field needs to delve 
deeper into the mechanistic underpinnings of the divergent actions of FMRP to gain a 
better grasp of FXS pathogenesis.  
One approach that addresses the nuances of FMRP function is a shift in focus 
from cell-autonomous to non-cell autonomous roles of FMRP. Several studies have 
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elucidated both pre- and post-synaptic requirements for FMRP (Gatto and Broadie, 2008; 
Schreiner et al., 2012). As such, examination of the extracellular synaptomatrix and the 
relevant trans-synaptic signaling pathways in dfmr1 mutant flies has provided a broader 
view of how FMRP acts on both sides of the synaptic cleft to impact neural architecture 
(Friedman et al., 2013). Several lines of evidence suggest that dysregulation of a class of 
membrane-bound proteins that bind ligands proximal to the cell surface to modulate 
downstream signaling pathways, collectively entitled heparin sulfate proteoglycans 
(HSPGs), may underlie the aberrant synaptogenesis present in FXS (Dani et al., 2012; 
Darnell et al., 2011). Central to this hypothesis, FMRP has been shown to bind to HSPG 
mRNA directly (Darnell et al., 2011). To test whether the absence of FMRP impacts 
HSPG levels and consequentially alters downstream trans-synaptic signaling, Friedman et 
al., conducted a series of experiments to evaluate the effect of genetic manipulation of 
these factors on NMJ structure and function (Friedman et al., 2013). First, Friedman et 
al., demonstrated that the synaptic HSPG co-receptors, Dally-like protein (Dlp) and 
Syndecan (Sdc), are upregulated in the NMJs of dfmr1 mutant flies (Friedman et al., 
2013). Next, they established that in the absence of dFMRP, trans-synaptic signaling was 
depressed in two parallel anterograde pathways that are regulated by the presynaptic 
ligands Wingless (Wg) and Jelly belly (Jeb). The altered abundance of Wg and Jeb in 
dfmr1 mutant flies resulted in reduced downstream signaling in postsynaptic muscle 
nuclei. In contrast, retrograde BMP signaling was not impaired in dfmr1 mutant flies. 
Taken together, these results suggest that dFMRP specifically alters anterograde trans-
synaptic signaling pathways. To validate the functional consequences of HSPG co-
receptor overexpression on synaptic morphology and function, Friedman et al., 
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genetically reduced HSPG co-receptor expression in the dfmr1 mutant background 
(Friedman et al., 2013). As expected, correction of HSPG co-receptor overabundance was 
sufficient to normalize synaptic overelaboration and mitigate elevations of 
neurotransmission in dfmr1 mutant NMJs. Moreover, this genetic manipulation restored 
the observed reductions in Wg and Jeb signaling to wild-type levels (Friedman et al., 
2013). These findings suggest a model in which dFMRP negatively regulates HSPG co-
receptor levels during synaptogenesis at the Drosophila NMJ. dFMRP then functions in a 
non-cell autonomous manner to modulate anterograde trans-synaptic signaling pathways 
and thereby ensure proper synaptic morphology and function. These findings in the 
Drosophila model of FXS provide the first mechanistic evidence that aberrant trans-
synaptic signaling is a causal factor in FXS pathogenesis. Importantly, the role of the 
extracellular synaptomatrix in the structural and functional maturation of synapses is 
conserved in mammals (Friedman et al., 2013). Thus, it will be important to determine 
whether these promising observations in the Drosophila model of FXS can be replicated 
in mammalian FXS models. Further investigation of trans-synaptic signaling may provide 
clinicians with additional therapeutic strategies to treat FXS. 
 
Behavioral Output Pathways 
Social Interaction and Memory 
 In accordance with the array of neuronal aberrations that occur in the absence of 
dFMRP, dfmr1 mutant flies exhibit abnormal behavior and cognition. Importantly, the 
behavioral and cognitive deficits observed in the Drosophila model of FXS are 
reminiscent of the symptoms seen in human patients (Bolduc et al., 2008; Dockendorff et 
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al., 2002; McBride et al., 2005). While at a superficial level it seems that alterations in 
neural circuitry are causative of the observed behavioral and cognitive defects, evidence 
suggests that this view is oversimplified. Rather, there are instances in which therapeutic 
interventions remedy behavioral but not neuroanatomical phenotypes in dfmr1 mutant 
flies (McBride et al., 2005). 
One behavior that is altered in dfmr1 mutant flies is courtship. An innate social 
program exists in Drosophila in which male flies court female flies using a stereotypical 
sequence of behaviors (Greenspan and Ferveur, 2000). When a female fly is receptive to 
the advances of a male fly, the male typically remains engaged in the courtship ritual 
until copulation is achieved. In contrast, dfmr1 mutant males quickly lose interest in 
social interaction with females in this courtship paradigm. As a result, dfmr1 mutant flies 
exhibit an overall decrease courtship levels and fail to proceed to the latter, more 
advanced stages of the courtship ritual (Dockendorff et al., 2002). Consistent with these 
observations, novel findings presented in Bolduc et al., indicate that dfmr1 mutant flies 
have an additional deficit in social interaction (Bolduc et al., 2010b). Specifically, Bolduc 
et al., found that dfmr1 mutant flies that are contained in a chamber are less likely to 
interact with conspecifics placed in an adjacent chamber than their wild-type counterparts 
(Bolduc et al., 2010b).  
In addition to the observed social deficits, dfmr1 mutant flies exhibit memory 
impairments as assessed using both odor-based classical and courtship-based 
conditioning paradigms. The basic premise of odor-based classical conditioning is that 
adult flies are exposed to two odors, one of which is paired with an electrical shock. After 
a training period, flies are queried for their ability to remember which of the two odors 
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was associated with the aversive stimulus during the training phase (Tully and Quinn, 
1985). In courtship-based testing, adult males are paired with an unreceptive female 
during training and are subsequently tested for a reduction in courtship amount when 
paired with a receptive female. It is thought that the suppression of courtship amount 
during the testing phase indicates that the male fly remembers the negative experience 
with an unreceptive female during training (Siegel and Hall, 1979). The length of time 
between the training and testing phases varies based upon the type of memory that is 
being assessed. Many studies that employed these memory assays found that dfmr1 
mutant flies exhibit deficits in immediate recall-, short-term-, and long-term memory 
(Banerjee et al., 2010; McBride et al., 2005). However, it should be noted that some 
manipulations that were found to ameliorate the observed memory deficits did not 
normalize defects in MB architecture (McBride et al., 2005). Further, it appears that the 
requirement for dfmr1 expression varies in subsets of neurons that comprise the MB. 
Specifically, concurrent dfmr1 expression in the α, β, and γ lobes of the MB in a genetic 
background that is otherwise dfmr1 mutant is sufficient to rescue olfactory learning 
defects. In contrast, restoration of dfmr1 expression in the γ lobes of the MB alone or in 
the ellipsoid body alone is not sufficient to rescue the observed olfactory learning defect 
(Kanellopoulos et al., 2012). Similarly, genetic knock down of dfmr1 expression in the α 
and β lobes of the MB was found to be detrimental to learning, whereas genetic knock 
down dfmr1 expression in the γ lobes of the MB or ellipsoid body had no negative effect 
on learning (Kanellopoulos et al., 2012). Thus, it is likely that multiple cell type-specific 
requirements for dfmr1 expression converge to regulate behavioral and cognitive output.  
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Studies of behavior and cognition in the Drosophila model of FXS have also 
allowed for the identification of signaling molecules that are dysregulated in the disease 
state. The results of these studies are highly relevant at the translational level, as they 
uncover novel target for therapeutic intervention. One molecule that has recently been 
implicated in FXS pathogenesis is cyclic AMP (cAMP). Multiple lines of evidences 
indicate that cAMP levels are decreased in the absence of dFMRP and that that the 
circadian oscillation of cAMP response element binding protein (CREB) is dampened in 
dfmr1 mutant flies (Dockendorff et al., 2002; Kelley et al., 2007). These pioneering 
studies prompted exploration of the therapeutic potential of pharmacological 
augmentation of cAMP levels. As part of my thesis work, I showed that treatment with 
Rolipram, a Phosphodiesterase-4 (PDE-4) inhibitor, pharmacologically restored cAMP 
levels in the dfmr1 mutant flies (Choi et al., 2015). Additional experiments in both the 
Drosophila and murine models of FXS demonstrated that treatment with Rolipram also 
normalized deficits in associative learning, memory, and mGluR-dependent long term 
depression (Choi et al., 2015; Kanellopoulos et al., 2012).  
 Moreover, recently published work from our laboratory has implicated the 
dysregulation of insulin signaling in disease pathology in the Drosophila model of FXS. 
Monyak et al., observed elevated levels of the main Drosophila insulin-like peptide, 
increased phosophoinositide-3 kinase (PI3K) activity, and increased levels of 
phosphorylated Akt in the brains of dfmr1 mutant flies (Monyak et al., 2016). These 
observations led to the striking discovery that genetic manipulations that reduce insulin 
signaling are sufficient to rescue memory deficits in dfmr1 mutants flies (Monyak et al., 
2016).  
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Circadian Rhythms and Sleep: 
 Although dfmr1 mutant flies display normal entrainment and circadian behavior 
in the presence of light cues, they are unable to maintain a free-running circadian rhythm 
in complete darkness (Dockendorff et al., 2002; Inoue et al., 2002; Morales et al., 2002). 
Despite this robust behavioral phenotype, the circadian clock in the CNS appears to 
function normally in dfmr1 mutant flies. Thus, it is likely that the observed arrhythmicity 
in the absence of light cues results from a defect in the circadian output pathway 
(Dockendorff et al., 2002; Inoue et al., 2002). To determine the mechanisms by which 
dfmr1 regulates circadian behavior, Monyak et al., conduced mapping studies to ascertain 
the spatial requirements for dfmr1 expression for normal circadian behavior (Monyak et 
al., 2016). Congruent with the observation that the circadian clock in the CNS is 
functional in dfmr1 mutants, restoration of dfmr1 expression in the circadian clock cells 
alone did not ameliorate the aberrant circadian behavior of dfmr1 mutant flies 
(Dockendorff et al., 2002; Monyak et al., 2016). Instead, similar to their findings 
regarding memory defects, genetic reduction of insulin signaling was sufficient to 
increase circadian rhythmicity (Monyak et al., 2016). 
Consistent with the observed arrhythmic behavior in the absence of light cues, 
circadian gene expression is altered in dfmr1 mutant flies (Xu et al., 2012).  In addition to 
differences in mRNA levels, the expression and processing of several miRNAs appear to 
be altered in a circadian manner in dfmr1 mutant flies (Xu et al., 2012). This finding is 
particularly interesting because it suggests that the interaction between dFMRP and the 
miRNA pathway functionally impacts circadian regulation of gene expression. In 
addition to defective circadian behavior, evidence suggests that dfmr1 mutant flies have 
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altered sleep profiles. Specifically, dfmr1 mutant flies have been shown to sleep longer 
than their wild-type counterparts (Bushey et al., 2009). The observed increase in total 
sleep appears to be largely due to a higher frequency of sleep episodes and occurs both in 
the presence and absence of light cues, indicating that it is mechanistically distinct from 
the circadian phenotype (Bushey et al., 2009). Moreover, dfmr1 mutant flies exhibit 
augmented resistance to arousal (van Alphen et al., 2013; Bushey et al., 2009). At the 
molecular level, sleep deprivation results in increased levels of dFMRP (Bushey et al., 
2009). Structurally, dFMRP has been shown to regulate the pruning of synaptic branches 
in response to sleep (Bushey et al., 2011). These results indicate that proper dfmr1 
expression plays a critical role in maintaining sleep levels and sleep-dependent synaptic 
homeostasis.  
Notably, the symptoms reported in children with FXS appear to contradict the 
sleep phenotype observed in dfmr1 mutant flies. For example, caregiver reports indicate 
that FXS patients have difficulty falling and asleep have frequent episodes of arousal 
during the night (Gould et al., 2000; Kronk et al., 2009, 2010). In contrast, it has been 
reported that FXS patients have relatively increased levels melatonin, a sleep-promoting 
hormone, throughout the circadian period (Gould et al., 2000). It is possible that these 
seemingly incompatible phenotypes can be explained by other medical problems such as 
sleep apnea, which appears to co-occur with sleeping difficulties in FXS patients (Kronk 
et al., 2009, 2010). Such contradictory results emphasize the limitations of subjective, 
self-reported phenotypic measures and illuminate the urgent need for the discovery of 
biomarkers, which would provide tools for more objective assessments. Moreover, they 
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highlight the necessity for more comprehensive studies of the FXS population to 
determine the prevalence of such disturbances.  
 
Response to Cellular Stress  
DNA Damage Response  
 Recently, it has been shown that dFMRP plays a role in the cellular response to 
DNA damage. Phenotypic evidence suggests that dfmr1 mutant flies are more susceptible 
to irradiation or mutagen-induced genotoxic stress than their wild-type counterparts (Liu 
et al., 2012). Moreover, in the absence of dFMRP, larval brain cells fail to arrest at the 
G2/M checkpoint in response to DNA damage (Liu et al., 2012). It is possible that this 
improper response is due in part to increased levels of cyclin B in dfmr1 mutant flies (Liu 
et al., 2012). Further evidence that dFMRP functions in the nuclear response to DNA 
damage comes from a recent study that demonstrated that damage induced by UV 
irradiation and pharmacological treatment with mutagenic compounds leads to increased 
nuclear localization of dFMRP and a greater amount of chromatin bound by dFMRP 
(Zhang et al., 2014). Consistent with these findings, dfmr1 mutant flies have little to no 
phosphorylation of H2AV, which is the Drosophila form of the mammalian histone 
variant H2AX. Loss of H2AV phosphorylation is particularly deleterious because when 
double-stranded breaks are induced in DNA, H2AV is activated by phosphorylation and 
proceeds to mediate the cellular response to DNA damage (Zhang et al., 2014). Much 
like what is observed in Drosophila, FMRP binds to chromatin and regulates H2AX 
phosphorylation in response to DNA in mammalian models (Alpatov et al., 2014). 
Interestingly, the prevalence of cancer appears to be decreased in FXS patients (Schultz-
Pedersen et al., 2001; Sund et al., 2009). Conversely, increased Fmr1 expression has been 
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correlated with increased tumor metastasis (Lucá et al., 2013). Since experimental 
evidence suggests that FMRP plays a role in the regulation of the DNA damage response 
and cancer susceptibility, these recently discovered functions of FMRP merit further 
exploration. 
 
Stress Granules  
 Several studies in mice have demonstrated that FMRP recruits mRNA into stress 
granules (SGs), which are foci for translational repression in response to cellular stress 
(Kim et al., 2006; Mazroui et al., 2002). However, these studies did not assess whether 
FMRP is critical for the formation of SGs. This question was addressed in a recent study 
in a Drosophila cell based model. The authors found that much like its mammalian 
counterpart, dFMRP is also recruited into SGs upon heat shock or other forms of cellular 
stress (Gareau et al., 2013). While it appears that dFMRP is dispensable for SG 
formation, Gareau et al., revealed that dFMRP shuttles in and out of SGs and identified 
the motifs in dFMRP that are important for these shuttling dynamics (Gareau et al., 
2013). This finding is exciting, as it is the first report of a protein that shuttles between 
RNA localized in SGs and the cytosol. 
 
Concluding Remarks 
Although disheartening, recent studies highlight the notion that dFMRP functions 
in an exquisitely cell type- and temporal-specific manner. Therefore, it is likely that 
apparent contradictions in the literature reflect the heterogeneity of dFMRP function in 
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different spatiotemporal contexts. Nevertheless, several exciting new discoveries in 
Drosophila and murine models of FXS have exposed nuances in FMRP activity.  
Given the myriad of phenotypes that have been documented in the clinical 
literature, it has become increasingly apparent that FXS is a systemic disorder. Despite 
this evidence, most research efforts have focused on the neurological aspects of FXS and 
many of the peripheral phenotypes have been ignored. In my thesis, I focused on 
identifying and characterizing peripheral metabolic phenotypes in the dfmr1 mutant flies 
to better understand the importance of dFMRP at the organismal level. In Chapter 2, I 
will describe the unbiased metabolomics approach that I used to identify changes in the 
global metabolome of the dfmr1 mutant flies and experiments that further validated these 
findings. I will also discuss a novel hyperphagia phenotype that I discovered in the dfmr1 
mutant flies that is reminiscent of the Prader-Willi Phenotype of FXS introduced in 
Chapter 1. Subsequently, in Chapter 3, I will present evidence that the loss of dFMRP 
impacts mitochondrial function and morphology. The work described in this thesis 
combines metabolomic and physiological approaches to decipher novel roles of dFMRP 
and establish a foundation for studies of the mechanisms by which metabolism and 
mitochondrial function contribute to the etiology of FXS and autism.   
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Figure 1.1. Classification of FMR1 alleles. The 5’ UTR of FMR1 contains a CGG 
trinucleotide expansion of variable length. In the typical population, the 5’ UTR contains 
less than 60 of these CGG repeats, which allows for normal expression of the FMR1 gene 
(top). Premutation alleles contain between 60 and 200 CGG trinucleotide repeats 
(middle). This moderate expansion is thought to result in increased transcription of FMR1 
and is associated with Fragile X Tremor/Ataxia Syndrome (FXTAS) and premature 
ovarian insufficiency (POI). In most FXS patients, the 5’ UTR of FMR1 contains over 
200 CGG trinucleotide repeats. This pathogenic lesion, termed the full mutation, leads to 
hypermethylation of the locus and subsequent transcriptional silencing of FMR1 
(bottom). 
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Figure 1.2. Conservation of functional motifs in FMRP. The FMR1 gene encodes for 
Fragile X Mental Retardation Protein (FMRP). FMRP contains three RNA-binding 
motifs. These motifs include two heterogeneous nuclear RNP K homology domains 
(KH1 and KH2), shown in blue, and an RGG box, shown in orange. FMRP also contains 
a nuclear localization signal (NLS), shown in green, and a nuclear export signal, shown 
in purple. While the localization of FMRP is primarily cytoplasmic, the NLS and NES 
allow FMRP to shuttle between the nucleus and the cytoplasm. The Drosophila homolog 
of FMRP, termed dFMRP, shares sequence identity and biochemical properties with 
human FMRP. To emphasize this high degree of conservation, the percent amino acid 
identity of each functional domain is indicated in the schematic.  
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Table 1.1. Comparison of phenotypes in Drosophila and mouse models of FXS with 
phenotypes seen in human patients. The development of Drosophila and murine 
models of FXS has enhanced our understanding of the ways in which the loss of FMRP 
contributes to the observed behavioral, cognitive, and neuroanatomical phenotypes. 
Notably, many of the phenotypes that FXS patients present with have correlates in the 
Drosophila and murine models. 
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CHAPTER 2: 
 
 
ENERGY METABOLISM AND FEEDING BEHAVIOR ARE ALTERED IN THE 
ABSENCE OF DROSOPHILA FRAGILE X MENTAL RETARDATION 
PROTEIN2  
																																								 																				
2 A significant portion of this chapter has been submitted for publication	
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Summary 
Fragile X Syndrome (FXS), the most prevalent form of inherited intellectual 
disability and the foremost monogenetic cause of autism, is caused by loss of expression 
of the FMR1 gene. In this Chapter, I show that dfmr1 modulates the global metabolome 
in Drosophila. Further, despite the previous discovery from our laboratory that brain 
insulin signaling is increased, my results indicate that dfmr1 mutants have reduced 
carbohydrate and lipid stores and are hypersensitive to starvation stress. The observed 
metabolic deficits cannot be explained by feeding behavior, as I report that dfmr1 mutants 
are hyperphagic. Taken together, these results illustrate the importance of dfmr1 for the 
proper maintenance of energy homeostasis and feeding behavior. 
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Introduction 
 The ability to coordinate and maintain energy homeostasis is essential to ensure 
the survival of an organism. Living organisms must be able to sense their nutritional 
status and balance energy needs with dietary input. Given the complexity of the pathways 
involved in cellular metabolism, the use of genetic model systems has greatly facilitated 
the elucidation of the central mechanisms that coordinate metabolic responses (Baker and 
Thummel, 2007; Schlegel and Stainier, 2007; Tennessen et al., 2014). Studies in 
Drosophila have uncovered aspects of metabolic control that are conserved through 
evolution. Many of the metabolic organs present in vertebrates have analogs in 
Drosophila (Figure 2.1 A) (Arrese and Soulages, 2010; Baker and Thummel, 2007; 
Padmanabha and Baker, 2014). Additionally, Drosophila share metabolic functions such 
as the conservation of storage and mobilization of energy reserves with vertebrate 
systems (Figure 2.1 B) (Arrese and Soulages, 2010; Baker and Thummel, 2007; 
Padmanabha and Baker, 2014). Thus, the Drosophila model system is a valuable tool to 
interrogate factors that are involved in the regulation of metabolism. 
As I discussed in Chapter 1, the first aim of my thesis project was to identify and 
characterize the metabolic phenotypes that arise in the absence of dFMRP. I was 
particularly intrigued to explore potential roles of dfmr1 in metabolism because of the 
disproportionate incidence of autism in patients that present with the Prader-Willi 
Phenotype of FXS (Hagerman et al., 2008; McLennan et al., 2011; Muzar et al., 2016). 
Moreover, our laboratory recently demonstrated that insulin signaling is dysregulated in 
the dfmr1 mutant flies (Monyak et al., 2016). Importantly, Monyak et al., showed that 
genetic reduction of insulin signaling is sufficient to ameliorate behavioral and cognitive 
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defects in dfmr1 mutant flies (Monyak et al., 2016). This remarkable finding suggests that 
insulin signaling dysregulation is relevant on a behavioral and cognitive level. 
Considering that proper regulation of insulin signaling is critical to maintain metabolic 
homeostasis, I hypothesized that metabolism would be altered in the dfmr1 mutant flies.  
 
Results 
dfmr1 regulates global metabolism 
To understand the role of dFMRP in the regulation of metabolic homeostasis I 
began with a broad, unbiased approach. Specifically, I asked whether I could detect 
differences in the global metabolome of flies with a loss-of-function mutation in the 
dfmr1 gene relative to iso31Bw- (wild-type) conspecifics. As an additional control I also 
included transgenic flies that contain a wild-type copy of the dfmr1 gene that has been 
inserted on another chromosome in a genetic background that is otherwise dfmr1 mutant, 
termed wild-type rescue (WTR) flies (Dockendorff et al., 2002). Since metabolism in 
Drosophila is modulated by circadian clocks, all flies were entrained on a strict 12:12 
light: dark (LD) cycle (DiAngelo et al., 2011; Xu et al., 2008). Moreover, to avoid any 
potential confounds due to age or gender, I limited my studies to 5 to 7-day old male 
flies. The 5 to 7-day age range was of particular interest to me because it is the age at 
which there are known neuroanatomical alterations and impairments in behavior and 
cognition (Dockendorff et al., 2002; McBride et al., 2005).  
Samples comprised of 50 whole flies per genotype were sent to Metabolon, Inc. to 
be extracted and loaded onto an ultrahigh performance liquid chromatography-tandem 
mass spectroscopy (UPLC-MS/MS) platform for global metabolic profiling. Analysts at 
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Metabolon utilized Principle Component Analysis (PCA) on the resultant datasets to 
determine whether it was possible to segregate samples of each genotype based solely on 
differences in their overall metabolite signature. Congruent with my hypothesis that 
global metabolism is altered in the absence of dFMRP, PCA analysis revealed a distinct 
separation between the dfmr1 mutant, wild-type, and WTR flies (Figure 2.2). The 
minimal overlap between the groups of 5 independent biological replicates of each 
genotype indicates that there is indeed a significant shift in the biochemical signature of 
the dfmr1 mutant flies relative to the wild-type and WTR controls. This novel finding 
suggests that in Drosophila, the loss of dFMRP substantially influences organismal 
physiology. My data are consistent with a previous report that the brains of Fmr1 null 
mice exhibit a distinct metabolic signature (Davidovic et al., 2011). Remarkably, the 
murine study also demonstrated that various brain regions are differentially affected by 
the absence of FMRP. Taking the exquisite spatiotemporal specificity of FMRP function 
alongside evidence of insulin signaling dysregulation in dfmr1 mutants (Monyak et al., 
2016), I decided to further probe metabolic alterations in the context of the periphery.  
 
Carbohydrate metabolism is deficient in the absence of dfmr1 
Encouraged by the discovery of global differences in the metabolome of the 
dfmr1 mutants, my next objective was to probe differences in specific subgroups of 
metabolites. Based upon the previous finding from our laboratory that insulin signaling is 
elevated in the brain of dfmr1 mutants, I was particularly eager to evaluate changes in 
carbohydrate metabolism (Monyak et al., 2016). Since proper regulation of insulin 
signaling is critical to maintain glucose homeostasis in mammals and Drosophila (Baker 
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and Thummel, 2007; Broughton et al., 2005; Rulifson et al., 2002; Schlegel and Stainier, 
2007), I hypothesized that glucose levels would be altered in the dfmr1 mutants. The data 
from Metabolon indicates that glucose and glucose 6-phosphate levels are dramatically 
decreased in the dfmr1 mutants relative to their wild type and WTR counterparts (Figure 
2.3 A-C, Table 2.2).  
To further explore alterations in carbohydrate metabolism, I next measured 
glycogen levels in the bodies of dfmr1 mutants and their wild type and WTR 
counterparts. Glycogen, which is a storage polymer of glucose, is the primary form of 
carbohydrate storage in Drosophila (Arrese and Soulages, 2010). Consistent with the 
observed decrease in its precursors, glucose and glucose 6-phosphate, dfmr1 mutants had 
drastically reduced levels of glycogen compared to the wild-type and WTR flies (Figure 
2.3 D). These alterations cannot be accounted for by differences in body size, as the 
weight of dfmr1 mutants is comparable to that of wild type flies (Figure 2.4 A). 
Moreover, notwithstanding the role of FMRP as a translational regulator, I did not detect 
any differences in overall protein levels when I measured overall protein levels for 
normalization purposes (Figure 2.4 B). Taken together, these results indicate that dfmr1 is 
a necessary regulator of carbohydrate metabolism.  
 
dfmr1 modulates lipid metabolism  
Next, I chose to investigate potential differences in lipid metabolism. Recently, 
lipids have emerged as a target of interest in FXS (Berry-Kravis et al., 2015; Lisik et al., 
2016; McMahon and Rosbash, 2016; Tabet et al., 2016a, 2016b). Contrary to the 
predominate view in the field that FMRP acts as a promiscuous RNA binding protein, 
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data from a novel cross-linking immunoprecipitation (CLIP) study suggest that FMRP 
preferentially associates with one mRNA target, diacylglycerol kinase kappa (dgkK), in 
cultured murine cortical neurons (Darnell et al., 2011; Tabet et al., 2016a). On a 
functional level, this contentious finding was reinforced by the discovery that human 
FMRP exhibited the highest binding affinity for the dgkk transcript in vitro (Tabet et al., 
2016a). Given that DGKK modulates balance between diacylglycerol and phosphatidic 
acid, both of which are critical components of membrane architecture and essential 
signaling molecules, the consequences of deregulation of DGKK could contribute 
substantially to FXS etiology (McMahon and Rosbash, 2016; Tabet et al., 2016a, 2016b). 
My whole-body metabolomics study in 5-7 day old flies detected significant 
reduction in 9 out of the 12 species of diacylglycerols measured in the dfmr1 mutants 
relative to wild-type and WTR controls (Figure 2.5 A-I, Table 2.2). Notably, these 
findings contradict the report of an increase in several species of diacylglycerols in 
cortical neuronal cultures derived from Fmr1 KO mouse embryos and cerebellar extracts 
from human FXS patients (Tabet et al., 2016a). This dichotomy emphasizes the notion 
that the loss of FMRP may precipitate differential effects depending upon spatiotemporal 
context. In addition to diacylglycerols, carnitine conjugated lipids were also diminished 
in the dfmr1 mutants (Figure 2.6 A-D, Table 2.2). These findings are notable because 
deleterious variants of genes involved in carnitine biosynthesis have been implicated in 
sporadic autism (Celestino-soper et al., 2010; Nava et al., 2012). 
Due to solubility constraints, Metabolon was unable to measure triglyceride levels 
in our metabolomics study. Triglycerides, which represent over 90% of stored lipids in 
Drosophila, have been shown to be tightly regulated by insulin signaling (Arrese and 
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Soulages, 2010; Baker and Thummel, 2007; Broughton et al., 2005; Schlegel and 
Stainier, 2007). Thus, to augment my metabolomics findings, I used another colorimetric 
assay to measure triglycerides in the bodies of dfmr1 mutant and control flies. Consistent 
with the observed decrease in diacylglycerols, I found that peripheral triglyceride levels 
were significantly reduced in dfmr1 mutants relative to wild-type controls (Figure 2.7). 
This finding is congruent with the observed decrease in glycogen levels (Figure 2.3 D) 
and indicates that the dfmr1 mutants have greatly diminished carbohydrate and lipid 
stores. 
 
Absence of dfmr1 increases sensitivity to starvation 
Next, I wanted to evaluate the functional implications of the observed reduction in 
energy stores. The ability to survive in the absence of nutrients is a robust paradigm to 
assess metabolic status, as starvation resistance is influenced by lipid and glycogen 
content (Bushey et al., 2009; Masek et al., 2014; Slocumb et al., 2015). To measure the 
response of the dfmr1 mutants and control flies to nutrient deprivation, I recorded the 
survival time of flies of each genotype on a 1% agar medium. Importantly, the 1% agar 
medium provided a uniform source of water such that any alterations in desiccation 
resistance did not confound my results (Tennessen et al., 2014). I found that the dfmr1 
mutants died much sooner than their wild-type and WTR counterparts when subjected to 
nutrient depravation. This result indicates that the dfmr1 mutants are hypersensitive to 
starvation conditions (Figure 2.8 A). Presumably, the observed reduction in carbohydrate 
and lipid storage renders the dfmr1 mutant flies less resistant to starvation conditions.  
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dfmr1 regulates feeding behavior 
The observed reductions in carbohydrates, lipids, and starvation resistance are the 
opposite of what I would expect to find under conditions of elevated insulin signaling 
(Table 2.1) (Baker and Thummel, 2007; Rulifson et al., 2002). Rather, my results suggest 
that the metabolic disturbances that occur in the absence of dfmr1 cannot be attributed to 
canonical insulin signaling hyperactivity. Intrigued by this dichotomy, I sought to better 
understand the mechanisms underlying the observed metabolic differences. 
The first hypothesis that our laboratory tested was the possibility that the dfmr1 
mutants are hyperactive and thereby deplete their available carbohydrate and lipid stores. 
To quantitate the average daily activity of dfmr1 mutant and wild-type flies, Dr. Rachel 
Monyak used the Drosophila Activity Monitoring (DAM) System. Rachel found that the 
average daily activity of the dfmr1 mutants was comparable to that of the wild-type flies 
in the presence of light: dark cues (Figure 2.8 B). Thus, we concluded that activity levels 
do not contribute substantially to the observed metabolic changes. 
Subsequently, I turned to feeding behavior to ascertain clues about the 
mechanistic underpinnings of the observed metabolic deficits. I used the well-established 
capillary feeder (CAFE) assay to quantitate the amount of 100 mM sucrose consumed by 
the dfmr1 mutant and wild-type flies (Ja et al., 2007). To induce detectable changes in 
feeding over time, I first starved flies for 12 hours on 1% agar. The 12 hour duration was 
selected because it is the time at which feeding behavior is driven by taste-independent 
mechanisms such that any differences in taste ability or preferences would not confound 
my results (Dus et al., 2011). The flies were then allowed to feed ad libitum on a highly 
appetitive 100 mM sucrose solution until this food source was exhausted. My results 
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indicate that initially total consumption was not significantly different between 
genotypes, which was not too surprising given that the prior 12 hours of starvation 
rendered both groups of flies primed to feed (Figure 2.8 C). However, as time progressed 
the dfmr1 mutants diverged significantly from their wild-type counterparts and consumed 
much more of the 100 mM sucrose (Figure 2.8 C). This striking discovery prompted me 
to delve deeper into the temporal dynamics of feeding behavior. To assess the feeding 
pattern of the dfmr1 mutant and wild-type flies, I quantified the amount of 100 mM 
sucrose consumed by each genotype every hour. This analysis revealed that wild-type 
flies ate the most during the first two hours of the assay and subsequently decreased 
feeding for the remainder of the assay (Figure 2.8 D). In contrast, the dfmr1 mutants 
sustained a high level of consumption for seven hours followed by a modest reduction in 
feeding for the last hour of the assay (Figure 2.8 D). Taken together, it appears that after 
acute starvation the dfmr1 mutants are unable to become sated and suppress feeding like 
their wild-type counterparts. This novel finding is highly reminiscent of reports in the 
clinical literature of FXS patients that fail to achieve satiety and instead eat to excess 
(Hagerman et al., 2008; Muzar et al., 2016; Nowicki et al., 2007).  
 
Discussion 
The findings presented in this Chapter reveal major changes in metabolism in a 
Drosophila model of FXS. While the implications of loss of dfmr1 are canonically 
considered in the context of the brain, I have identified important physiological changes 
that occur at the systemic level in the absence of dFMRP. Here, I report a shift in the 
global metabolome of dfmr1 mutant flies. My metabolomics data along with colorimetric 
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quantification of glycogen and triglycerides provide compelling evidence that 
carbohydrates and lipids are dramatically reduced in the dfmr1 mutants. These results are 
consistent with observation that that the body composition of Fmr1/Fxr2 double-
knockout mice is characterized by reduced fat deposits as well as low plasma glucose, 
glycerol, free fatty acids, and cholesterol (Lumaban and Nelson, 2015). Moreover, a 
retrospective study in a large cohort of adults with FXS found that total cholesterol (TC), 
low density lipoprotein (LDL) and high density lipoprotein (HDL) were all significantly 
reduced in males with FXS relative to population normative data (Berry-Kravis et al., 
2015). Remarkably, this study concluded that unlike findings in the general population, 
there was no relationship between lipid levels and body mass index (BMI) (Berry-Kravis 
et al., 2015). The lack of a relationship between lipid levels and BMI in the FXS cohort 
raises the possibility that the mechanism by which decreased lipid levels occur in FXS is 
independent of BMI. Importantly, the apparent evolutionary conservation of these deficits 
between flies, mice, and humans suggests that impairments in carbohydrate and lipid 
homeostasis are a robust feature of FXS pathophysiology. 
In further support of my finding that energy stores are decreased in the dfmr1 
mutants, I also present evidence that dfmr1 mutant flies exhibit augmented sensitivity to 
nutrient deprivation. Given that the ability to store and mobilize nutrients regulate the 
response to starvation conditions, it is likely that deficient energy storage underlies the 
diminished ability of the dfmr1 mutants to withstand starvation conditions. Efforts to 
determine the mechanistic underpinnings of the observed metabolic phenotypes lead to 
the striking discovery that food consumption is substantially elevated in the dfmr1 mutant 
flies. Further, I identified a highly significant difference in feeding rate whereby unlike 
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their wild-type counterparts, the dfmr1 mutants fail to become sated and do not suppress 
feeding at later time points. Notably, a modest increase in ad libitum food intake was 
noted in Fmr1/Fxr2 double-knockout mice (Lumaban and Nelson, 2015). However, the 
effect was much subtler than what I observed, likely because the static measurement of 
total daily food consumption precluded the ability to capture differences in feeding 
dynamics over time. My results are particularly relevant on a translational level because 
the feeding phenotype that we identified in our Drosophila model is highly reminiscent 
of the Prader-Willi Phenotype of FXS. Given that there is a disproportionate prevalence 
of autism in FXS patients that present with the Prader-Willi Phenotype (Hagerman et al., 
2008; McLennan et al., 2011; Muzar et al., 2016; Nowicki et al., 2007), I believe that I 
have identified a robust paradigm to evaluate the efficacy of certain therapeutic 
interventions on FXS and autism pathogenesis. 
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Figure 2.1. Comparison of metabolism in mammals and Drosophila. (A) Unlike in 
mammalian systems, pancreatic function in Drosophila is mediated by the insulin 
producing cells (IPCs) in the brain and the corpora cardiaca (CC) in the adjacent ring 
glad. The Drosophila abdominal fat body is analogous to the mammalian white adipose 
tissue. Both the abdominal fat body and oenocytes serve as Drosophila analogs to the 
mammalian liver. The Drosophila gut functions similarly to its mammalian counterpart. 
(B) In the fed state, insulin is released from the IPCs and travels through the hemolymph 
to the abdominal fat body whereby it promotes the storage of carbohydrates as glycogen 
and lipids primarily as triglycerides. In contrast, in the fasted state, adipokinetic hormone 
(AKH) functions comparably to mammalian glucagon and travels from the ring gland to 
the abdominal fat body to promote the mobilization of stored carbohydrates and lipids. 
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Figure 2.2. dfmr1 mutant flies have a distinct biochemical profile. Principal 
Component Analysis (PCA) was used as an unsupervised mathematical tool to assess 
whether the 5 independent biological replicates of each genotype, depicted as colored 
circles, segregate and cluster based on differences in their overall metabolite signature. 
Principle components are defined as a unique linear combination of every metabolite. 
Each principal component has one dimension and a midpoint =0. Variance was computed 
as the square of the standard deviation, whereby total variance was the sum of the 
variances of the predicted value for each individual component. The percentage that 
Component 1 and Component 2 contributed to the total variance is shown on the x and y-
axes, respectively. Dashed lines indicate distinct groups. The genotypes shown are: 
iso31Bw- (WT), wild-type rescue (WTR), and dfmr1 mutant (dfmr13). 
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Figure 2.3. Carbohydrate levels are decreased in dfmr1 mutant flies. A-C. (A) Box 
plot legend, (B) quantification of glucose, and (C) glucose 6-phosphate levels in 5 
independent biological replicates of each genotype. Box plots depict the scaled intensity 
value of each metabolite on the y-axis. Genotype is denoted on the x-axis. Fold change is 
summarized in Table 2.2. (D) Glycogen levels were measured in 5-7 day old male flies of 
different genotypes. The resultant values were then normalized to protein content. Fly 
heads were removed prior to homogenization. Sample number (N) per genotype = 5. 
Each sample contained an independent group of four fly bodies. One-way ANOVAs 
revealed a significant group effect for glycogen (p<0.0001). Post hoc Tukey tests 
indicated that dfmr1 mutant flies had reduced levels of glycogen compared to iso31Bw- 
and WTR flies. Values represent mean ± SEM. *** p≤0.001, **** p≤0.0001 
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Figure 2.4. Weight and protein levels are unchanged in the dfmr1 mutant flies. (A) 
Weight was measured in 5-7 day old male flies. Sample number (N) per genotype: 
iso31Bw- = 17, dfmr13 = 13. Each sample contained an independent group of 20 flies. 
Mann-Whitney test results indicated that there was no difference in weight between the 
dfmr1 mutant flies iso31Bw- control flies (p=0.0797). Data shown represent the 
cumulative results of 4 independent experiments. (B) Protein levels were measured in 5-7 
day old male flies. Fly heads were removed prior to homogenization. Sample number (N) 
per genotype: iso31Bw- = 35, dfmr13 = 29. Each sample consisted of one fly. Mann-
Whitney test results indicated that there was no difference in protein levels between the 
dfmr13 mutant and iso31Bw- control flies (p=0.2113). Data shown represent the 
cumulative results of 3 independent experiments. Values represent mean ± SEM. 
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Figure 2.5. Diacylglycerol levels are diminished in the dfmr1 mutant flies. (A-I) The 
name of each of the distinct diacylglycerol species measured in 5 independent biological 
replicates of each genotype is listed above its corresponding box plot. Scaled intensity 
value of is indicated on the y-axis. Genotype is denoted on the x-axis. Fold change is 
summarized in Table 2.2. Welch’s two-sample t-test was used to identify significant 
differences in the metabolite ratios. For all 9 diacylglycerol species shown here, the 
metabolite ratio was less than 1.00 and there was a significant difference between the 
iso31Bw- and dfmr13 mutant flies (p£0.05). There were no statistically significant 
differences between the iso31Bw- and WTR flies (p>0.05). 
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Figure 2.6. Carnitine-conjugated lipids are reduced in the dfmr1 mutant flies. (A-D) 
The name of each of the four carnitine-conjugated lipids measured in 5 independent 
biological replicates of each genotype is listed above its corresponding box plot. Scaled 
intensity value of is indicated on the y-axis. Genotype is denoted on the x-axis. Fold 
change is summarized in Table 2.2. Welch’s two-sample t-test was used to identify 
significant differences in the metabolite ratios. For all four species, the metabolite ratio 
was less than 1.00 and there was a significant difference between the iso31Bw- and 
dfmr13  flies (p£0.05). There were no statistically significant differences between the 
iso31Bw- and WTR flies (p>0.05). 
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Figure 2.7. Triglyceride stores are depleted in the dfmr1 mutant flies. Triglyceride 
levels were measured in 5-7 day old male flies of different genotypes. The resultant 
values were then normalized to protein content. Fly heads were removed prior to 
homogenization. Sample number (N) per genotype: iso31Bw- = 35, dfmr13 = 29. Each 
sample contained one fly body. Mann-Whitney test results indicated that dfmr1 mutant 
flies had reduced levels of triglycerides compared to iso31Bw- flies (p=0.0061). Data 
shown represent the cumulative results of 3 independent experiments. Values represent 
mean ± SEM. **p≤0.01, ***   
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Figure 2.8. dfmr1 mutant flies are more sensitive to starvation despite hyperphagia. 
(A) Starvation resistance was measured by recording the average survival time of 5-7 day 
old males of each genotype on media containing 0% sucrose and 1% agar. Sample 
number (N) per genotype: iso31Bw- = 99, dfmr13 = 160, WTR= 53. Log-rank (Mantel-
Cox) test results indicated that dfmr13 mutants were less resistant to starvation than the 
iso31Bw- (p≤0.0001) and WTR (p≤0.0001) flies.  
(B) The activity of 3 to 7 day old flies was measured using activity monitors. Data were 
collected from day 2 to day 6 whereby daily activity was defined as the sum of all beam 
breaks that occurred during a 24-hour period. The daily activity of each fly was then 
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averaged over the 5 days used for analysis. Sample number (N) for both genotypes = 85. 
Mann-Whitney test results indicated that there was no difference in activity between the 
dfmr13 mutant flies iso31Bw- control flies (p=0.7874). Data shown represent the 
cumulative results of 3 independent experiments. (C) The total amount of 100mM 
sucrose consumed was measured every 30 minutes. All values recorded were then 
normalized to an evaporation control. Sample number (N) per genotype = 3. Each sample 
contained an independent group of 35 flies. Two-way ANOVA found that the interaction 
between the relative total amount consumed and genotype to be highly significant (p< 
0.0001). Asterisks denote significant differences in the relative consumption of dfmr3 
mutants compared to that of iso31Bw- flies as determined using Sidak’s multiple 
comparison test. (D) Hourly consumption was determined by subtracting the total 
consumption from the preceding hour from the total consumption each hour. Two-way 
ANOVA found that for both genotypes, the interaction between amount consumed and 
time to be highly significant (p< 0.0001). Statistical significance for the amount 
consumed each hour compared to consumption during the first hour of the assay was 
determined using Sidak’s multiple comparison test. Values represent mean ± SEM. 
*p≤0.05, **p≤0.01, ***p≤0.001, ****p< 0.0001 
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Table 2.1. The observed metabolic phenotypes are inconsistent with canonical 
insulin signaling hyperactivity. The effects of insulin signaling on metabolism have 
been well documented and there are several predictions that can be made about what to 
expect in a scenario when insulin signaling is elevated. Given the previous finding from 
our laboratory that brain insulin signaling appears to be increased in the dfmr1 mutant 
flies, I anticipated that I would observe an increase in carbohydrates and lipids coupled 
with a consequent increase in starvation resistance and weight. However, my data 
indicate that carbohydrate and lipid levels are decreased in the dfmr1 mutant flies. 
Congruent with reduced energy stores, the dfmr1 mutant flies are less resistant to 
starvation. Moreover, I did not observe a difference in weight. These findings suggest 
that insulin signaling is not uniformly elevated and/or that there is another mechanism 
underlying the observed metabolic differences.  
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Super Pathway Sub Pathway Biochemical Name dfmr1
3 
iso31Bw- 
dfmr13 
WTR 
WTR 
iso31Bw- 
Carbohydrate 
Glycolysis, 
Gluconeogenesis, and 
Pyruvate Metabolism 
glucose 0.74 0.71 1.05 
glucose 6-phosphate 0.50 0.62 0.81 
Lipid 
Diacylglycerol 
diacylglycerol 
(14:0/18:1, 
16:0/16:1) [1] 
0.58 0.58 1.01 
diacylglycerol 
(16:1/18:2 [2], 
16:0/18:3 [1])* 
0.48 0.50 0.98 
oleoyl-linoleoyl-
glycerol  
(18:1/18:2) [1] 
0.46 0.53 0.86 
oleoyl-linoleoyl-
glycerol  
(18:1/18:2) [2] 
0.55 0.57 0.97 
palmitoleoyl-
linoleoyl-glycerol 
(16:1/18:2) [1]* 
0.39 0.42 0.93 
palmitoyl-oleoyl-
glycerol  
(16:0/18:1) [2]* 
0.45 0.41 1.09 
palmitoleoyl-oleoyl-
glycerol  
(16:1/18:1) [1]* 
0.14 0.15 0.94 
palmitoleoyl-oleoyl-
glycerol  
(16:1/18:1) [2]* 
0.34 0.42 0.82 
palmitoyl-linoleoyl-
glycerol  
(16:0/18:2) [2]* 
0.55 0.50 1.11 
Fatty Acid Metabolism 
(Acyl Carnitine) 
acetylcarnitine 0.76 0.70 1.09 
myristoylcarnitine 0.17 0.27 0.65 
palmitoylcarnitine 0.30 0.43 0.71 
palmitoleoyl-
carnitine* 0.20 0.27 0.73 
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Table 2.2. Summary of changes in a small subset of the carbohydrates and lipids 
profiled in the metabolomics study. Welch’s two-sample t-test was used to identify 
significant differences in the metabolite ratios. Boxes shaded in green indicate a 
significant difference (p£0.05) in which the metabolite ratio was less than 1.00. The light 
red box indicates a metabolite that narrowly missed the statistical cutoff for significance 
(0.05<p<0.10) in which the metabolite ratio was greater than 1.00. Boxes without color 
represent mean values that were not significantly different. * denotes a compound that 
has not been confirmed based on a standard but is of known identity.  
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Materials and Methods 
Fly genetics and husbandry 
Fly strains that contain the dfmr13 allele and WT rescue transgene are described in 
Dockendorff et al., (Dockendorff et al., 2002). These flies were outcrossed to 
w1118(iso31Bw-) flies as described in Monyak et al., (Monyak et al., 2016). The fly 
strains were cultured on a standard cornmeal-molasses medium and maintained in the 
presence of stringent 12 hours light: 12 hours dark (LD) cycles at 25°C.  
 
Metabolomics 
5 to 7 day old adult male flies were collected on dry ice. Flies of each genotype were 
pooled into five independent groups comprised of 50 flies. These samples were then sent 
for biochemical profiling at Metabolon, Inc., where they were extracted and prepared as 
described in Evans et al., (Evans et al., 2009). Briefly, the extract from each sample was 
divided into four fractions: one for analysis by UPLC-MS/MS with positive ion mode 
electrospray ionization, one for analysis by UPLC-MS/MS with negative ion mode 
electrospray ionization, one for analysis by GC-MS, and one sample was reserved for 
backup. Raw data was extracted, peak-identified, and QC processed using Metabolon’s 
proprietary hardware and software. The resultant dataset was comprised of 373 
compounds of known identity, termed named biochemicals. Following log transformation 
and, if necessary, imputation with minimum observed values for each compound, 
Welch’s two-sample t-tests were used to detect biochemicals that differed significantly 
between the following comparisons: iso31Bw- and dfmr13; WTR and dfmr13; and 
iso31Bw- and WTR. 
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Glycogen Measurement 
5 to 7 day old adult male flies were collected on dry ice. Fly heads were removed prior to 
homogenization, as the presence of eye pigment can interfere with accurate absorbance 
measurements (Tennessen et al., 2014). The decapitated fly bodies were placed in groups 
of four and homogenized in 200 µL of 0.1M NaOH. The homogenate was then 
centrifuged at 15871 x g for 10 minutes at 4C°. The supernatant was extracted from each 
sample and 20 µL of the lysate was treated with 5 mg/mL Amyloglucosidase (Sigma-
Aldrich, Saint Louis, MO) in 0.2 M acetate, pH 4.8, as this enzyme catabolizes glycogen 
to yield free glucose molecules. Concurrently, another 20 µL aliquot of the lysate was 
treated with 0.2 M acetate, pH 4.8 alone. Both reactions incubated for 2 hours at 37C°. 
Subsequently, the free glucose content in each reaction was measured in triplicate with 
the Amplex Red Glucose/Glucose Oxidase Assay kit (Molecular Probes, Eugene, OR). 
The protein concentration of these reactions was then determined with the Pierceâ BCA 
Protein Assay Kit (Thermo Scientific, Rockford, IL) for normalization. The glycogen 
content of each sample was calculated by subtracting the free glucose concentration of 
the untreated lysate from the free glucose concentration of the lysate that was treated with 
amyloglucosidase.  
 
Triglyceride Measurement 
Triglyceride levels were measured as described in DiAngelo and Birnbaum (DiAngelo 
and Birnbaum, 2009). Briefly, individual 5 to 7 day old adult male flies were collected on 
dry ice. Fly heads were removed prior to homogenization, as the presence of eye pigment 
can interfere with accurate absorbance measurements(Tennessen et al., 2014). The 
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decapitated fly bodies were then homogenized in lysis buffer that contained 140mM 
NaCl, 50mM Tris-HCL, pH 7.4, 20% Triton X-100, and 1X protease inhibitors (Roche, 
Indianapolis, IN). The homogenate was then centrifuged at 15871 x g for 10 minutes at 
4C°. Triglyceride concentrations were determined in triplicate with the Triglyceride 
LiquiColor kit (Stanbio Laboratory, Boerne, TX). The protein concentration of each 
sample was measured with the Pierceâ BCA Protein Assay Kit (Thermo Scientific, 
Rockford, IL). The triglyceride concentration of each sample was then normalized to its 
respective protein content. 
 
Starvation Resistance 
5 to 7 day old adult male flies were reared on standard medium. These flies were 
subsequently transferred in groups of 20 to plastic vials that contained a 1% agar 
medium. All starvation vials were maintained in the presence of stringent 12 hours light: 
12 hours dark cycles at 25°C. The number of dead flies in each vial was recorded every 
12 hours until 100% mortality was attained. Mortality was defined as the cessation of 
locomotion.  
 
Weight Measurement 
5 to 7 day old adult male flies were placed in 1.5 mL microcentrifuge tubes in groups of 
20. Each sample was then weighed on a Mettler AE 100 Analytical Balance.  
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Feeding Behavior 
5 to 7 day old adult male flies were reared on standard medium. These flies were 
subsequently transferred in groups of 35 to starvation vials that contained a 1% agar 
medium for 12 hours prior to testing. A modified version of the Capillary Feeder (CAFE) 
assay described in Ja et al., (Ja et al., 2007) was used to measure ingestion of liquid food 
from a graduated glass microcapillary (WPI, Sarasota, FL). Briefly, flies were cold-
anesthetized and transferred to empty vials with a cappilary affixed to the top as 
explained in Itskov and Ribiero and Masek et al., (Itskov and Ribeiro, 2013; Masek et al., 
2014). Each capillary was filled with liquid food comprised of 100 mM sucrose and blue 
dye for visualization. The amount of food consumed every half hour was monitored by 
measuring the level of the meniscus of the liquid in each capillary every half hour. All 
recorded values were normalized to an evaporation control that contained no flies as 
described in Xu et al., (Xu et al., 2008).  
 
Activity Levels 
Male flies of the appropriate genotype were collected 0-4 days post eclosion and 
entrained to a stringent 12 hours light: 12 hours dark cycle for three days at 25°C. Flies 
were then placed in individual tubes containing 5% sucrose, 2% agar, and loaded into 
monitors (Trikinetics, DAM2 system, Waltham, MA) that were returned to a light:dark 
cycle at 25°C. The activity of these flies, as indicated by beam breaks, was measured 
from days 2 to 6. The daily activity of each fly was averaged over the 5 days used for 
analysis, and the average daily activity of each genotype was determined. Flies that died 
at any time during the assay were excluded from analysis. 
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Statistics 
For the metabolomics data, standard statistical analyses were performed in ArrayStudio 
on log transformed data. The programs R (http://cran.r-project.org/) and JMP were used 
for analyses that are not standard in ArrayStudio. Welch’s two sample t-tests were used 
to identify biochemicals that differed significantly between genotypes. For all other 
experiments, the Prism software package (GraphPad Software, v7.0b) was used to 
generate graphs and perform statistical analyses. Unpaired t-tests were used to evaluate 
pairwise comparisons. Multiple comparisons were investigated using one-way analysis of 
variance (ANOVA) with post hoc Tukey tests or two-way ANOVA with a post hoc Sidak 
tests. The log- rank (Mantel-Cox) test was used to examine differences in starvation 
resistance between genotypes. 
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CHAPTER 3: 
 
 
DROSOPHILA FRAGILE X MENTAL RETARDATION PROTEIN 
MODULATES MITOCONDRIAL FUNCTION AND MORPHOLOGY3  
																																								 																				
3 A significant portion of this chapter has been submitted for publication	
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Summary 
In Chapter 2, I showed that the dfmr1 mutant flies have a distinct biochemical 
signature. My experiments revealed that whole-body carbohydrate and lipid levels are 
diminished in the absence of dFMRP. The observed decrease in energy stores in the 
dfmr1 mutants was accompanied by an increase in sensitivity to starvation stress. 
Paradoxically, I found that the dfmr1 mutants ate significantly more than their wild-type 
counterparts. To better understand the molecular mechanisms underlying the observed 
changes in peripheral metabolism, I have begun to explore the possibility that aberrant 
mitochondrial function contributes to FXS pathophysiology. In this chapter, I 
demonstrate that the redox ratio of an important mitochondrial cofactor, nicotinamide 
adenine dinucleotide (NAD), is lower in the dfmr1 mutant flies. Moreover, I reveal that 
maximum electron transport system (ETS) capacity is elevated in the dfmr1 mutant flies, 
despite an apparent decrease in the expression of a protein that is critical for the catalytic 
activity of a component of the electron transport chain. Finally, I present electron 
micrographs that display striking morphological changes in the mitochondria that 
surround thoracic myofibrils in the dfmr1 mutant flies. Taken together, these results 
illustrate the importance of dfmr1 for proper mitochondrial function and morphology. 
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Introduction  
One mechanism by which metabolism has been shown to influence behavioral 
output is through the modulation of energy production. In cells, mitochondria are the 
incredibly dynamic, double membrane bound organelles responsible for the conversion of 
dietary calories into useable energy in the form of adenosine triphosphate (ATP) (Valenti 
et al., 2014; Wallace, 2001). Mitochondrial number varies by cell type whereby tissues 
that have the greatest energetic demands contain more mitochondria than less energetic 
tissues (Wallace, 2005). The molecular machinery responsible for the generation of 
energy is localized in cristae, which are structures formed by the inner mitochondrial 
membrane (Mattson et al., 2008). The cristae contain five protein complexes that are 
arranged in an assembly line-like manner that, together, are called the electron transport 
chain (ETC) (Mattson et al., 2008). The ETC carries out oxidative phosphorylation 
(OXPHOS) during which reducing equivalents, in the form of hydrogen derived from 
carbohydrates and fats, are oxidized and combined with atomic oxygen to produce ATP, 
water, and reactive oxygen species (ROS) (Wallace, 2001, 2011). The flow of electrons 
through the ETC releases energy that is used to pump protons out of the mitochondrial 
inner membrane and generate an electrochemical gradient that allows for the efficient 
coupling of electron transport to ATP synthesis (Wallace, 2005).  
Recently, a growing body of evidence has implicated mitochondrial dysfunction 
in the pathogenesis of intellectual disability related syndromes and autism (Valenti et al., 
2014; Wallace, 2005, 2011; Wallace and Fan, 2010). While the central nervous system 
(CNS) is thought to represent a mere 2% of total body weight, it is estimated to consume 
around 20% of inspired oxygen at rest (Valenti et al., 2014). This high oxidative demand 
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renders the CNS particularly sensitive to changes in mitochondrial metabolism (Valenti 
et al., 2014). Proper mitochondrial function is especially critical for the establishment of 
neuronal connectivity, neurogenesis, synaptic plasticity, and apoptosis (Mattson et al., 
2008; Valenti et al., 2014). Impairments of the mitochondrial OXPHOS apparatus have 
been attributed to the pathophysiology of Down Syndrome, Rett Syndrome, and 
idiopathic autism (Valenti et al., 2014). The conservation of mitochondrial dysfunction in 
several neurodevelopmental and neurodegenerative disorders suggests that these distinct 
syndromes share common molecular features (Wallace, 2005, 2011). Thus, I reasoned 
that mitochondrial function could be altered in the dfmr1 mutant flies.  
 
Results 
dfmr1 modulates nicotinamide adenine dinucleotide (NAD) metabolism 
Since the observed metabolic differences presented in Chapter 2 could not be 
explained by activity levels or feeding behavior, I speculated that mitochondrial 
dysfunction could contribute to FXS pathogenesis in our Drosophila model. In support of 
this hypothesis, my metabolomics data suggest that nicotinamide adenine dinucleotide 
(NAD) metabolism is regulated by dfmr1. Specifically, I found that both nicotinic acid 
adenine dinucleotide (NAAD+) and NAD+ levels were greatly diminished in the dfmr1 
mutants relative to wild-type and WTR control flies (Figure 3.1 A-C, Figure 3.1 F). 
Importantly, the concomitant decrease in the levels of NAAD+ and NAD+ suggests that 
NAD biosynthesis is impaired in the dfmr1 mutants. Compromised NAD biosynthesis 
would be particularly problematic given that mitochondrial ATP production and 
membrane potential maintenance require NAD+ as a cofactor (Stein and Imai, 2012). As 
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such, the observed decrease in NAAD+ and NAD+ levels in the absence of dFMRP may 
have deleterious consequences for mitochondrial bioenergetics. 
 To delve deeper into changes in NAD metabolism, I subsequently measured the 
NAD+/NADH redox ratio. During the tricarboxylic acid (TCA) cycle, NAD+ gains two 
electrons and a proton, thereby being reduced to NADH (Figure 3.1 F). In turn, NADH 
ferries the two electrons that it gained to the electron transport chain (ETC), whereby it is 
oxidized back to NAD+. The reliance of the TCA cycle and the ETC on NAD+ and 
NADH, respectively, underscores the importance of the maintenance of the optimal 
NAD+/NADH ratio for mitochondrial function. Based upon this knowledge and my 
finding that NAD+ levels are diminished in the dfmr1 mutants (Figure 3.1 B, F), I 
hypothesized that the absence of dFMRP would result in a decreased NAD+/NADH ratio. 
Consistent with my metabolomics data, I observed a significant decrease in NAD+ levels 
(Figure 3.1 B, C, F). Additionally, I found that NADH levels were significantly 
augmented in the dfmr1 mutants (Figure 3.1 D, F). The combined diminution of NAD+ 
levels and elevation of NADH levels results in a dramatically reduced NAD+/NADH 
ratio in the dfmr1 mutants compared to wild-type flies (Figure 3.1 E, F). 
 
dfmr1 is important for maximum electron transport system (ETS) capacity 
In further support of the notion that mitochondrial metabolism is altered in the 
absence of dFMRP, it has been shown that dfmr1 negatively regulates microtubule 
dependent mitochondrial transport (Yao et al., 2011). Thus, I reasoned that other 
mitochondrial functions could be altered in the dfmr1 mutant flies. To explore this 
possibility, I collaborated with the laboratory of Dr. Douglas Wallace at the Children’s 
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Hospital of Philadelphia (CHOP) to perform high-resolution respirometry (HRR) on fresh 
thoracic mitochondrial preparations from dfmr1 mutant and wild-type flies. Together, we 
utilized the substrate-uncoupler-inhibitor titration (SUIT) protocol, which allows for real-
time interrogation of mitochondrial oxygen flux (Pesta and Gnaiger, 2012; Votion et al., 
2012). We found that within the parameters of the HRR assay, the dfmr1 mutant 
mitochondria have a significantly increased maximum electron transport system (ETS) 
capacity relative to wild-type flies (Figure 3.2). This discovery was unexpected 
considering my NAD+/NADH results (Figure 3.1), as the rapid oxidation of NADH to 
NAD+ is necessary to sustain increased ETS capacity. 
Notably, the observed increase in maximum ETS capacity was not accompanied 
by any statistically significant differences in oxygen flux in the presence of Complex I 
and/or Complex II driven substrates, including the TCA cycle intermediates malate and 
succinate. Similarly, my metabolomics data revealed that the levels of TCA cycle 
intermediates in the dfmr1 mutants were comparable to those of wild-type flies (Table 
A.1). However, the levels of TCA cycle intermediates that I observed in my 
metabolomics analysis likely represent the steady-state concentrations of these 
biochemicals at the time that the samples were prepared. As such, flux analysis on the 
various intermediates would provide a more sensitive readout of TCA cycle activity in 
the dfmr1 mutants. Further, considering that the TCA cycle occurs in mitochondria, the 
quantification of the levels of TCA cycle intermediates in enriched mitochondrial 
preparations would be more likely to detect changes in the levels of these specific 
biochemicals than whole organism studies. 
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Moreover, while the observed increase in maximum ETS capacity appears to be 
inconsistent with my observation that the NAD+/NADH ratio is diminished in the dfmr1 
mutants, I cannot rule out the possibility the methodology used in these experiments 
precluded my ability to detect such changes. Specifically, the SUIT protocol involves the 
sequential addition of supersaturating concentrations of mitochondrial substrates, 
uncouplers, and inhibitors to enriched mitochondrial preparations that are no longer in the 
tissue from which they have been extracted. Thus, the data obtained using this technique 
do not necessarily reflect alterations that occur under physiological conditions. 
Additionally, the NAD+/NADH data cannot be directly compared the HRR results, as the 
HRR experiments were performed using mitochondrial extracts whereas the 
measurement of NAD+/NADH levels was performed using whole-body lysates. 
Importantly, the pool of mitochondrial NAD+ and NADH is kept separate from that of the 
cytosol (Stein and Imai, 2012). Given that the levels of NAD+ and NADH are much 
higher in the cytosol than in mitochondria, the dramatic changes that I observed likely 
reflect alterations in cytosolic levels of NAD+ and NADH (Stein and Imai, 2012). Further 
studies of the mitochondrial pool of NAD in the dfmr1 mutants will be necessary to 
reconcile the apparent discrepancy between our observations regarding NAD+/NADH 
levels and maximum ETS capacity. 
 
The expression of succinate dehydrogenase B (SDHB) is altered in dfmr1 mutants 
 Given that the HRR data indicate that maximum ETS capacity is elevated in the 
dfmr1 mutants, I next used western blotting to probe the protein levels of components of 
the ETC. I chose to focus on Complex II, termed Succinate Dehydrogenase (SDH), for 
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several reasons. First, unlike the other members of the ETC, the subunits of SDH are 
exclusively encoded by nuclear DNA (Rutter et al., 2010). As such, the mRNA 
transcripts of the SDH subunits must traverse the cytosol prior to translation and import 
into the mitochondrial inner membrane. Coupled with the known role of dFMRP as an 
RNA-binding protein that is highly expressed in the cytoplasm, it is possible that the loss 
of dFMRP-mediated translational regulation of SDH subunits has deleterious 
consequences for mitochondrial function. Moreover, SDH is unique in that it is the only 
respiratory enzyme that participates in both the TCA cycle and OXPHOS (Rutter et al., 
2010). In this way, SDH serves as a direct link between glycolysis and mitochondrial 
respiration (Rutter et al., 2010). 
 The SDH holocomplex is comprised of four subunits (Rutter et al., 2010; Walker 
et al., 2006). The SDHA and SDHB subunits are hydrophilic and function as the catalytic 
flavoprotein and iron-sulfur center of SDH, respectively (Walker et al., 2006). In 
contrast, SDHC and SDHD are the hydrophobic intermembrane proteins that anchor the 
SDH holocomplex to the mitochondrial inner membrane (Rutter et al., 2010). I elected to 
assay the levels of the catalytic core components, SDHA and SDHB, because these 
subunits are essential for SDH activity. Congruent with the finding that oxygen flux in 
the presence of Complex I and II driven substrates is comparable between mitochondrial 
extracts from the dfmr1 mutant and control flies (Figure 3.2), there was no difference in 
SDHA protein levels between the dfmr1 mutants and their wild-type counterparts (Figure 
3.3 A, B). Unexpectedly, I detected a significant reduction in the expression of SDHB in 
the dfmr1 mutants (Figure 3.3 A, EC). This finding was surprising, as it seems to be 
inconsistent with the observed increase in maximum ETS capacity. However, the HRR 
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data cannot be directly compared to my western blot results, as the HRR experiments 
were performed using mitochondrial extracts whereas the measurement of SDH subunit 
expression was performed using whole-body lysates. The interpretation of this data is 
also limited by fact that western blotting is not the most quantitative technique. 
Additionally, protein levels are not necessarily correlated with enzymatic activity. Rather, 
further studies of SDH activity in the dfmr1 mutants will be necessary to reconcile the 
apparent discrepancy between my observations regarding maximum ETS capacity and 
SDHB expression. 
  
dfmr1 mutants have aberrant mitochondrial morphology 
To further investigate the consequences of loss of dFMRP on mitochondria in 
situ, I collaborated with the Electron Microscopy Resource Laboratory at the University 
of Pennsylvania and used Transmission Electron Microscopy (TEM) to examine 
mitochondrial morphology in the dfmr1 mutant and wild-type flies. For this analysis, we 
prepared longitudinal sections of Drosophila indirect flight muscle, as this tissue has high 
energy demands that require robust mitochondrial function (Clark et al., 2006) (Figure 
3.4 A). We first examined mitochondrial ultrastructure, as proper spatial arrangement 
informs mitochondrial function. In the wild-type flies, we observed densely packed 
mitochondria that were evenly aligned with and distributed along the length of the 
adjacent myofibrils (Figure 3.4 B). However, the mitochondrial ultrastructure of the 
dfmr1 mutants revealed severe pathology that was characterized by variable, frequently 
smaller mitochondria that were irregularly spaced (Figure 3.4 C, D). We also noticed that 
several of the dfmr1 mutant mitochondria had aberrant morphology (Figure 3.4 C, D). 
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Images taken at higher magnification revealed that sections of the dfmr1 mutant 
mitochondria had localized disruptions in the cristae (Figure 3.4 F, G). The loosely 
disbursed cristae in the dfmr1 mutants were in sharp contrast to the densely-packed 
cristae present in wild-type mitochondria (Figure 3.4 E). As I explain in more detail in 
Chapter 4, I believe that it is likely that these morphological changes affect mitochondrial 
function. 
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Discussion 
The discovery that the NAD+/NADH ratio is dramatically reduced in the dfmr1 
mutants, paired with the knowledge that mitochondria generate energy by oxidizing 
hydrogen supplied by carbohydrates and fats, prompted me to collaborate with members 
of the University of Pennsylvania and CHOP communities to utilize two distinct 
approaches to investigate the possibility that mitochondrial function is altered in the 
dfmr1 mutant flies. Surprisingly, our experiments revealed that maximum electron 
transport system (ETS) capacity is significantly increased in thoracic mitochondria 
isolated from dfmr1 mutants. The apparent contradiction between the diminished ratio of 
NAD+/NADH and the observed elevation of maximum ETS capacity in the dfmr1 
mutants provides a compelling foundation for follow-up studies to determine the 
directionality of changes in mitochondrial respiration. This can be accomplished by 
measuring the enzymatic activity level of each component of the electron transport chain. 
If hyper-respiration is observed, it will be critical to determination of ATP levels in dfmr1 
mutants to ascertain whether the mitochondria are effectively coupled. Without proper 
coupling, any increase in the utilization of reducing equivalents for electron transport 
would fail to yield commensurate levels of ATP. Further studies will also be necessary to 
reconcile the observed elevation in maximum ETS capacity with the apparent decrease in 
SDHB expression.  
Moreover, we observed striking aberrations in the morphology of mitochondria in 
lateral sections of indirect flight muscle. Considering that ultrastructure and function are 
intimately linked, it is conceivable that the pathological changes that we uncovered 
greatly impact mitochondrial energy production. In support of the notion that 
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mitochondrial function is compromised in the absence of dFMRP, it has been shown 
previously that flight ability is impaired in dfmr1 mutants (Zhang et al., 2001). 
Ultimately, the findings presented here raise several important questions regarding the 
ways in which FMRP shapes the metabolic landscape. Notably, the extent to which 
mitochondrial dysfunction impinges on peripheral metabolism and the mechanisms by 
which dFMRP regulates these processes remain to be determined. In Chapter 4, I will 
discuss several experimental approaches to augment our understanding of these lingering 
questions. From a translational standpoint, the most relevant application of the results 
presented in this Chapter would be the discovery of genetic and/or pharmacological 
manipulations that rescue metabolism, mitochondrial function, and the observed 
behavioral and cognitive phenotypes.  
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Figure 3.1 NAD metabolism is reduced in dfmr1 mutant flies. A, B. (A) 
Quantification of NAAD+ and (B) NAD+ levels in 5 independent biological replicates of 
each genotype. Box plots depict the scaled intensity value of each metabolite on the y-
axis. Genotype is denoted on the x-axis. C-E, (C) Quantification of NAD+, (D) NADH, 
and (E) NAD+/NADH. The levels of NAD+ and NADH were normalized to protein 
content. Each sample contained 10 fly bodies. Sample number (N) per genotype = 3. 
Unpaired t-tests indicated that NAD+ levels were very significantly diminished 
(p=0.0094), NADH levels were significantly elevated (p=0.0238), and the reduction of 
the NAD/NADH ratio was extremely significant (p=0.0002) in the dfmr1 mutants relative 
to iso31Bw- controls. (F) Schematic illustrating the relationship between NAAD+, NAD+, 
and NADH. Green type signifies biochemicals that were lower in the dfmr1 mutants 
compared to control flies. Red type indicates a biochemical that was augmented in the 
dfmr1 mutants relative to control flies. Values represent mean ± SEM. *p≤0.05, 
**p≤0.01, ***p≤0.001  
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Figure 3.2 Maximum electron transport system (ETS) capacity is augmented in the 
dfmr1 mutant flies. (A) Oxygen flux was measured in mitochondrial preparations from 
fly thoraces and subsequently normalized to mitochondrial protein content. Maximum 
ETS capacity was defined as the rate of oxygen consumption after the addition of FCCP. 
ROX represents the non-mitochondrial residual oxygen consumption rate after the 
addition of Rotenone and Antimycin. Sample number (N) per genotype for complex I, 
cytochrome c, complex I+II, ETS = 6 for both genotypes. Sample number (N) per 
genotype for ROX = 5 for both genotypes. Each sample was comprised of mitochondria 
isolated from 50 flies. Two-way ANOVA found the interaction between genotype and 
oxygen flux to be very significant (p=0.0023). Post hoc Sidak’s multiple comparison test 
results indicated that maximum ETS capacity was significantly elevated in the dfmr1 
mutant flies compared to the iso31Bw- control flies. Data shown represent the cumulative 
results of 6 independent experiments. Values represent mean ± SEM. *p≤0.05 
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Figure 3.3 SDHB expression is decreased in the absence of dFMRP. A-C, Extracts 
were prepared from iso31Bw- and dfmr1 mutant flies for Western analysis. Each sample 
contained 3 decapitated fly bodies. Sample number (N) per genotype = 4 for both 
genotypes. (A) Representative western blot. The genotype of each sample is denoted by 
the bars above the image. The primary antibody used for detection is indicated to the left 
of the corresponding band. (B) SDHA levels were quantified and normalized to those of 
b-tubulin. Unpaired t-test results indicated that SDHA levels were not significantly 
different between the dfmr13 mutant and the wild-type control flies. (C) SDHB levels 
were quantified and normalized to those of b-tubulin. Unpaired t-test results indicated 
that SDHB levels are significantly decreased in the dfmr13 mutant flies compared to their 
wild-type counterparts (p=0.009). Values represent mean ± SEM. **p≤0.01 
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Figure 3.4 dfmr1 mutant mitochondria have aberrant morphology. (A) Longitudinal 
sections of indirect flight muscle were prepared from isolated thoraces (dashed box) for 
transmission electron microscopy experiments. The inset depicts a sagittal view of the 
thoracic musculature. Imaging was performed on the region illustrated in dark blue. B-D, 
Electron micrographs of Drosophila flight muscle at 7,500x magnification. (B) iso31Bw- 
and (C, D) dfmr13 mutant mitochondria, M, are aligned between rows of myofibrils, F. 
Scale bar indicates 2 microns. E-G, Electron micrographs of Drosophila flight muscle at 
20,000x magnification. (E) iso31Bw- and (F, G) dfmr13 mutant mitochondria at higher 
magnification. Scale bar indicates 500 nm. Arrows denote local disruptions in cristae. 
Asterisks signify marked dispersions of cristae.  
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Materials and Methods 
Fly genetics and husbandry 
Fly strains that contain the dfmr13 allele and WT rescue transgene are described in 
Dockendorff et al., (Dockendorff et al., 2002). These flies were outcrossed to 
w1118(iso31Bw-) flies as described in Monyak et al., (Monyak et al., 2016). The fly 
strains were cultured on a standard cornmeal-molasses medium and maintained in the 
presence of stringent 12 hours light: 12 hours dark (LD) cycles at 25°C.  
 
Metabolomics 
5 to 7 day old adult male flies were collected on dry ice. Flies of each genotype were 
pooled into five independent groups comprised of 50 flies. These samples were then sent 
for biochemical profiling at Metabolon, Inc., where they were extracted and prepared as 
described in Evans et al., (Evans et al., 2009). Briefly, the extract from each sample was 
divided into four fractions: one for analysis by UPLC-MS/MS with positive ion mode 
electrospray ionization, one for analysis by UPLC-MS/MS with negative ion mode 
electrospray ionization, one for analysis by GC-MS, and one sample was reserved for 
backup. Raw data was extracted, peak-identified, and QC processed using Metabolon’s 
proprietary hardware and software. The resultant dataset was comprised of 373 
compounds of known identity, termed named biochemicals. Following log transformation 
and, if necessary, imputation with minimum observed values for each compound, 
Welch’s two-sample t-tests were used to detect biochemicals that differed significantly 
between each genotype. 
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NAD+/NADH Quantification 
The concentrations of nicotinamide nucleotides were measured using the NAD+/NADH 
Quantification Colorimetric Kit (BioVision, Milpitas, CA) as described in Balan et al 
(Balan et al., 2008). Briefly, adult male flies aged 5 to 7 days were collected on dry ice. 
Fly heads were removed prior to homogenization and the decapitated fly bodies were 
pooled in groups of 10. The samples were homogenized in 400 µL of the NADH/NAD 
Extraction Buffer supplied in the kit and the homogenate was centrifuged at 18407 x g 
for 5 minutes at 25C° to remove debris. The cycling reaction was carried out as per the 
manufacturer’s instructions for 2 hours and the nicotinamide nucleotide concentrations 
were determined in duplicate. The protein concentration of each sample was measured 
with the Pierceâ BCA Protein Assay Kit (Thermo Scientific, Rockford, IL). The 
concentration of nicotinamide nucleotide contained in each sample was then normalized 
to its respective protein content. 
 
Mitochondrial Preparation 
Adult male flies aged 5 to 7 days were dissected to yield 50 thoraces per genotype. The 
dissected thoraces were then homogenized in a 1.5 mL micro centrifuge tube that 
contained 100 µl of a chilled mitochondrial isolation medium (MIM) comprised of 250 
mM sucrose, 10 mM Tris-HCl pH 7.4, 0.15 mM MgCl2, and a protease inhibitor cocktail 
(Roche, Indianapolis, IN). After careful homogenization, an additional 500 µl of MIM 
was added and the homogenate was centrifuged at 500 x g for 5 min at 4˚C. The 
supernatant was then transferred to a fresh micro centrifuge tube and centrifuged at  
5000 x g for 5 min at 4˚C. The resultant pellet containing the crude mitochondrial 
96 
	
fraction was washed with 500 µL MIM and resuspended in 115 µL of 1X PBS. 15 µL of 
this mitochondrial suspension was reserved for protein estimation using the Pierceâ 
BCA Protein Assay Kit (Thermo Scientific, Rockford, IL). The remaining 100 µl of the 
mitochondrial suspension was loaded onto the Oroboros-O2k HRR chamber for further 
analysis.  
 
Mitochondrial Oxygen Flux Using High-Resolution Respirometry (HRR) 
The mitochondrial preparations obtained from 50 fly thoraces per genotype were 
resuspended in MiRO5 buffer comprised of 0.5 mM EGTA, 3 mM MgCl2, 60 mM K-
lactobionate, 20 mM taurine, 10 mM KH2PO4, 20 mM Hepes, 110 mM sucrose and 1 g/L 
BSA essentially fatty acid free adjusted to pH 7.1(Gnaiger et al., 2000; Votion et al., 
2012). Oxygen concentration was monitored using the OROBOROS® Oxygraph-2k 
(O2k, Oroboros Instruments, Innsbruck, Austria) in accordance with a previously 
published protocol(Pesta and Gnaiger, 2012). Briefly, the oxygen electrodes were 
calibrated as per manufacturer instructions with an air-saturated respiration medium 
(MiRO5) at 25 °C prior to all experiments. A substrate-uncoupler-inhibitor titration 
(SUIT) protocol was used to evaluate mitochondrial respiratory function. First, to each 
chamber Complex I substrates 5 mM pyruvate, 2 mM malate, 10 mM glutamate were 
added. Next, the Complex II substrate 10 mM succinate was added.  To stimulate 
maximal oxygen flux, ADP (1-5 mM) was added after the addition of Complex I and II 
substrates. Next, the respiration uncoupler Carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (CCCP) was titrated in 0.1 µM steps to obtain 
maximum electron transport capacity (ETC).  Finally, all respiration was blocked by 
97 
	
addition of the complex I inhibitor 0.5 µM rotenone, the complex II inhibitor 5 mM 
malonic acid, and the complex III inhibitor 2.5 µM antimycin A. To ensure that the 
mitochondrial membrane integrity was not compromised, a 10 µM cytochrome c was 
added in each experiment to be sure that respiration was not stimulated.  The rate of 
oxygen consumption, termed oxygen flux, as a function of time was then normalized to 
the mitochondrial protein concentration of each sample. Data were analyzed by DatLab 
software (v5.0, Oroboros Instruments, Innsbruck, Austria). All chemicals were purchased 
from Sigma-Aldrich, USA. 
 
Western Blotting 
The heads were removed from 3 adult male flies and extracts were prepared from the 
bodies using extraction buffer (20 mM Hepes (pH 7.5), 100 mM KCl, 5% glycerol, 100 
µM NA3VO4, 10 mM EDTA, 0.1% Triton X, 1 mM DTT, and Complete Protease 
Inhibitor (Roche)). 4X LDS (Invitrogen) and 10X Reducing Agent (Invitrogen) were 
added before samples were boiled for 5 minutes to denature and reduce. Samples were 
separated on a 4-12% Bis-Tris gel (Invitrogen) and transferred to a PVDF membrane 
(Immobilon-P, Millipore). Enhanced chemiluminescence (SuperSignal West Pico; 
Thermo Scientific) was used for antibody detection. The following primary antibodies 
were used: anti-dfmr1 5A11 (1:2000; DSHB), anti-SDHA (1:2000; Abcam), anti-SDHB 
(1:2000) anti-β-tubulin E7 (1:20,000; DSHB). 
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Transmission Electron Microscopy 
Tissues for electron microscopic examination were fixed with 2.5% glutaraldehyde, 2.0% 
paraformaldehyde in 0.1M sodium cacodylate buffer, pH7.4, overnight at 4°C. After 
subsequent buffer washes, the samples were post-fixed in 2.0% osmium tetroxide for 1 
hour at room temperature, and then washed again in buffer followed by dH2O. After 
dehydration through a graded ethanol series, the tissue was infiltrated and embedded in 
EMbed-812 (Electron Microscopy Sciences, Fort Washington, PA). Thin sections were 
stained with lead citrate and examined with a JEOL 1010 electron microscope fitted with 
a Hamamatsu digital camera and AMT Advantage image capture software. 
 
Statistics 
For the metabolomics data, standard statistical analyses were performed in ArrayStudio 
on log transformed data. The programs R (http://cran.r-project.org/) and JMP were used 
for analyses that are not standard in ArrayStudio. Welch’s two sample t-tests were used 
to identify biochemicals that differed significantly between genotypes. For all other 
experiments, the Prism software package (GraphPad Software, v7.0b) was used to 
generate graphs and perform statistical analyses. Unpaired t-tests were used to evaluate 
pairwise comparisons. Multiple comparisons were investigated using one-way analysis of 
variance (ANOVA) with post hoc Tukey tests or two-way ANOVA with a post hoc Sidak 
tests.  
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CHAPTER 4: 
 
 
FUTURE DIRECTIONS AND CONCLUDING REMARKS 
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Introduction  
 For my thesis project, I utilized the powerful Drosophila model system to explore 
perturbations in metabolic homeostasis and mitochondrial function in FXS. While a 
substantial body of the scientific literature explores mechanisms by which FMRP 
regulates neuronal function and architecture, there is a paucity of information about the 
involvement of FMRP in peripheral tissues. To address this knowledge gap, I leveraged 
metabolomic and physiological approaches to elucidate novel roles of FMRP in 
Drosophila. In Chapter 2, I showed that dfmr1 mutant flies have a distinct biochemical 
profile. I also demonstrated that energy stores and resistance to starvation are decreased 
in the dfmr1 mutant flies, despite increased ad libitum food intake. Subsequently, in 
Chapter 3, I provided several lines of evidence that suggest that mitochondrial function 
and morphology are altered in the absence of dFMRP. These results are exciting, as they 
are at the intersection of metabolism, mitochondrial function, and disease 
pathophysiology. In this Chapter, I will discuss promising avenues for further inquiry and 
my overall conclusions. 
  
Future Directions 
Assess commonalities and differences in brain and peripheral metabolism in dfmr1 
mutants  
 In Chapter 2, I identified and characterized metabolic differences in peripheral 
tissues in the dfmr1 mutant flies. I elected to focus on peripheral phenotypes because I 
was interested in uncovering roles for dFMRP outside the context of the brain, as 
peripheral functions of FMRP have historically been ignored by the FXS field. Intrigued 
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by the elevated incidence of autism in FXS patients that present with the Prader-Willi 
Phenotype along with the recent identification of dgkk as a potentially preferential target 
of FMRP (Hagerman et al., 2008; Tabet et al., 2016a), I postulated that an assessment of 
peripheral metabolism in the dfmr1 mutant flies would provide valuable novel insights 
into systemic phenotypes that arise in the absence of dFMRP.  
Given that dFMRP acts with high spatiotemporal specificity, it is possible that the 
metabolic and mitochondrial aberrations that I observed in the periphery differ from those 
that occur in the brain. Consistent with this notion, studies in Fmr1 KO mice revealed 
that even in the central nervous system (CNS) there is differential modulation of 
neurotransmitter levels in distinct brain regions (Davidovic et al., 2011). This finding 
underscores the importance of examining metabolism and mitochondrial function in 
multiple tissue types. As such, to thoroughly characterize the metabolic and 
mitochondrial phenotypes of the dfmr1 mutant flies, it is essential that future studies 
repeat the experimental approaches that I discussed in Chapters 2 and 3 in other tissues. 
From a behavioral and cognitive standpoint, the brain is the most relevant tissue to focus 
on next. As I mentioned in Chapter 3, proper CNS function relies on the availability of 
metabolites and mitochondria that are poised to generate maximal quantities of ATP. In 
Drosophila, the metabolic demand of the brain is so great that there is a separate fat body 
in the head that is positioned to rapidly supply energy stores to the adjacent neurons. 
Certainly, there is a lot to be gained by extending the findings presented in my thesis to 
the CNS. However, from a technical perspective, studies in the brain will necessitate 
substantially more flies than those needed for whole fly and/or decapitated fly analysis. 
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While not insurmountable, further optimization will be required to obtain sufficient 
quantities of tissue for each assay.  
 
Determine the spatial requirements for dfmr1 expression 
 One of the many advantages of the Drosophila model system is the wealth of 
genetic tools that allow cell type- and tissue-specific expression of genes of interest. To 
direct gene expression, enhancer-trap lines have been generated in which the yeast 
transcriptional activator Gal4 is positioned under the control of a tissue specific promoter 
(St Johnston, 2002). When a GAL4 enhancer trap line is mated to transgenic flies that 
have the upstream activating sequence (UAS) to which Gal4 binds inserted next to a gene 
of interest, this pairing drives the expression of the gene of interest in a tissue specific 
manner (St Johnston, 2002).  
Mapping studies conducted with the enhancer-trap system have provided valuable 
insight into the mechanism by which dfmr1 regulates behaviors such as sleep (Monyak et 
al., 2016). Similarly, a genetic screen has the potential to illuminate cells and/or tissues in 
which dfmr1 expression is required to maintain metabolic homeostasis. Such information 
would allow for the elucidation of cell autonomous and cell non-autonomous 
requirements for dfmr1 expression. To this end, it would be interesting to assess whether 
the expression of a UAS-dfmr1 transgene under the control of the elav-Gal4 pan-neuronal 
driver is sufficient to rescue any of the observed peripheral metabolic phenotypes in a 
genetic background that is otherwise dfmr1 mutant.  If so, it would be informative to 
screen other Gal4 drivers that are specific to different subsets of cells in the CNS to hone 
in on precise circuit-level changes. Notably, reintroducing dfmr1 into the insulin 
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producing cells (IPCs) would best complement the previous studies from our laboratory 
of insulin signaling dysregulation in the dfmr1 mutant flies (Monyak et al., 2016). 
However, as I covered in Chapter 2, the inconsistencies between my data and the 
expectations under conditions of elevated insulin signaling suggest that there is another 
mechanism underlying the peripheral metabolic phenotypes. Thus, I do not expect the 
reintroduction of dfmr1 into the IPCs to rescue peripheral metabolism. Likewise, it is also 
possible that the cells that require dfmr1 to maintain peripheral metabolic homeostasis are 
epistatic to the IPCs. In this case, the enhancer-trap method can be used to examine 
neuronal populations that synapse onto the IPCs, such as the small ventrolateral neurons 
(sLNvs) and octopaminergic neurons. Glial cells also merit evaluation, as they are the 
main site of glycogen storage in the brain. 
Moreover, considering that cross-talk between the brain and periphery informs 
cellular decisions to store or mobilize nutrients (Géminard et al., 2009; Sousa-Nunes et 
al., 2011), future studies should assess whether restoration of dfmr1 in peripheral tissues 
ameliorates the observed metabolic, mitochondrial, and/or behavioral and cognitive 
defects in the dfmr1 mutants. My preliminary data suggest that re-introduction of dfmr1 
in the abdominal fat body is not sufficient to rescue the depletion of triglycerides 
(Appendix B). However, whether this result applies to other metabolic phenotypes such 
as diminished glycogen levels remains to be determined. Other peripheral tissues that 
would be particularly interesting for mapping studies of the requirements for dfmr1 in the 
maintenance of metabolic homeostasis are the oenocytes, gut, and muscle.  
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Investigate whether the fat body clock is functional in dfmr1 mutant flies 
 While the circadian clock in the CNS is the main circadian pacemaker, there are 
also circadian clocks located in peripheral tissues such as the abdominal fat body. 
Remarkably, it has been shown that the clock in the CNS and the clock in the abdominal 
fat body work in opposition to control metabolism (Xu et al., 2008). Specifically, Xu et 
al., found that flies that have an intact clock in the CNS clock but lack a functional clock 
in the abdominal fat body have decreased glycogen and triglyceride stores and reduced 
resistance to starvation stress (Xu et al., 2008). Despite these metabolic phenotypes, flies 
with an ablated abdominal fat body clock eat significantly more than their wild-type 
counterparts (Xu et al., 2008). Together, these findings are reminiscent of the data that I 
showed in Chapter 2. As such, it is possible that a disruption in the abdominal fat body 
clock of the dfmr1 mutants underlies the observed energy storage deficits and 
hyperphagia phenotype. In support of this notion, the cyclic pattern of abundance of core 
clock component transcripts is altered in the liver of Fmr1/Fxr2 double knock out mice 
(Zhang et al., 2008). Evidence from our laboratory suggests that the CNS clock functions 
normally in the dfmr1 mutant flies (Dockendorff et al., 2002). Thus, an examination of 
the levels and oscillations of the core clock genes, period and timeless, and the respective 
proteins that they encode in the abdominal fat body would afford a more complete picture 
of circadian function in the dfmr1 mutant flies.  
 Should any differences be detected in the abdominal fat body clock in the absence 
of dFMRP, environmental and genetic approaches can be used to determine the extent to 
which peripheral clock abnormalities contribute to the observed metabolic phenotypes. 
For example, Xu et al., showed that while the ablation of the CNS clock or the peripheral 
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clock independently had metabolic repercussions, concomitant disruption of both the 
CNS clock and the abdominal fat body clock resulted in normal metabolism (Xu et al., 
2008). In this way, ablation of the CNS clock in the dfmr1 mutants using conditions of 
constant darkness and/or the expression of a dominant negative clock transgene may 
mitigate the observed metabolic defects. Although the experiments described here would 
provide insight into the cellular and molecular underpinnings of the phenotypes that I 
report, the next steps remain unclear as the mechanism by which clock in the CNS and 
the clock in the abdominal fat body oppose each other remains unknown. 
 
Evaluate the coupling efficiency of dfmr1 mutant mitochondria 
 As I discussed in Chapter 3, protons are pumped out of the mitochondrial inner 
membrane to create an electrochemical gradient whereby the flow of electrons through 
the ETC is coupled to ATP synthesis (Wallace, 2005). When the mitochondrial inner 
membrane is leaky for protons, this short-circuits the capacitance across the membrane 
and uncouples electron transport from ATP synthesis (Wallace, 2005). Uncoupling is 
particularly challenging for cellular survival because when mitochondria are uncoupled, 
the ETC operates at its maximum rate and consumes large amounts of oxygen without 
generating a commensurate amount of ATP (Wallace, 2005). Our finding that maximum 
ETS capacity is elevated in dfmr1 mutant mitochondria raises the possibility that the 
dfmr1 mutant mitochondria are uncoupled. However, my observation that the 
NAD+/NADH redox ratio is significantly lower in the dfmr1 mutants is inconsistent with 
the hypothesis that dfmr1 mutant mitochondria are uncoupled, as increased oxidation of 
NADH to NAD+ would be necessary to support maximal ETS capacity.  
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 The first step towards evaluating coupling efficiency in FXS is the quantification 
of ATP levels in the dfmr1 mutant flies compared to wild-type conspecifics. If the dfmr1 
mutant mitochondria are uncoupled, it is possible that the dfmr1 mutant flies will have 
lower ATP levels than wild-type conspecifics. Another useful tool to assess coupling, 
albeit in a slightly less direct fashion, is to use JC-1 dye to measure the mitochondrial 
inner membrane potential. In this case, a finding of decreased mitochondrial inner 
membrane potential in the dfmr1 mutant flies would be indicative of uncoupling. Most 
relevant to my thesis, it would be fascinating to determine whether treatments that reverse 
uncoupling, such as dietary nitrates or genetic reduction of uncoupling proteins, rescue 
any of the metabolic or mitochondrial phenotypes that I identified in the dfmr1 mutant 
flies. To this end, measurement of the NAD+/NADH ratio, ATP levels, and/or the 
mitochondrial membrane potential can be used as a readout of the efficacy of 
manipulations aimed at improving mitochondrial function. Notably, any treatments that 
ameliorate mitochondrial dysfunction should be tested to determine whether they also 
mitigate the metabolic and/or behavioral phenotypes observed in models of FXS. 
 
Determine the precise mechanism by which the loss of dFMRP impinges on the ETC 
 The data presented in Chapter 3 provide a compelling argument that further 
studies of mitochondrial function in the dfmr1 mutant flies are warranted. Most 
importantly, the enzymatic activity of each of the respiratory complexes of the ETC 
should be measured in the dfmr1 mutant flies relative to their wild-type counterparts. I 
believe that it is likely that the diminished levels of SDHB that I observed in the dfmr1 
mutant flies may result in an overall reduction in SDH activity. While less direct, the 
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redox ratio of the SDH cofactor flavin adenine dinucleotide (FAD) can also be measured 
to approximate relative SDH activity levels. 
Moreover, considering my observation that SDHB protein levels are decreased in 
the dfmr1 mutant flies, it is possible that dfmr1 promotes the translation of sdhb mRNA 
transcripts. To test this hypothesis, future studies should use quantitative RT-PCR to 
determine whether there are any changes in the levels of sdhb transcripts. If dFMRP 
directly promotes the translation of sdhb, I do not anticipate that there will be any 
changes in the abundance of sdhb mRNA levels in the dfmr1 mutant flies compared to 
their wild-type counterparts. However, if dFMRP is involved in transcriptional regulation 
of sdhb, the abundance of sdhb mRNA levels in the dfmr1 mutant flies would differ from 
that of their wild-type counterparts. 
Additionally, the aberrant mitochondrial morphology that I discovered in the 
thoracic mitochondria of the dfmr1 mutants resembles that of the Drosophila hyperswirl 
mutants. Notably, hyperswirl mutants exhibit pathological “swirl” lesions within an 
otherwise normal mitochondrion. Further immuno-electron microscopy analysis revealed 
that this swirl morphology was associated with localized loss of Complex IV, cytochrome 
c oxidase (COX), activity (Jiang et al., 2017; Walker and Benzer, 2004). The 
heterogeneity of COX activity within the same mitochondrion raises the possibility that 
activity assays performed on mitochondrial preparations will not be sufficiently sensitive 
to detect more subtle, localized disruptions. This technical challenge can be circumvented 
by employing multiple approaches, such as immuno- electron microscopy and standard 
biochemical activity assays, in parallel. If differences are observed in the activity of one 
or more of the enzymes of the ETC, follow-up studies of the corresponding mRNA and 
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protein levels would provide additional mechanistic information. Considering that 
dFMRP is a known translational regulator, it is possible that dfmr1 modulates 
mitochondrial function by regulating the expression of multiple proteins involved in 
OXPHOS. 
 The identification of precise changes in OXPHOS in the dfmr1 mutants will 
provide a foundation for mechanistic studies that assess the link between mitochondrial 
dysfunction and metabolic alterations in FXS. There are many known interventions that 
either augment or dampen the activity of each of the enzymes of the ETC. Thus, 
elucidation of specific alterations in the ETC will enable future studies to determine 
whether the normalization of aberrations in the OXPHOS apparatus is sufficient to 
restore the observed metabolic, behavioral, and/or cognitive deficits in the dfmr1 mutant 
flies. 
 
Ascertain whether the dfmr1 mutants have elevated levels of reactive oxygen species 
(ROS) 
 An excess of reactive oxygen species (ROS) is another potential mechanism by 
which alterations in mitochondrial bioenergetics could promote FXS pathogenesis. The 
mitochondria are the primary endogenous source of ROS, which are formed as a toxic 
by-product of OXPHOS (Wallace, 2001). Consequently, several studies have determined 
that excessive ROS production by defective OXPHOS machinery is involved in the 
pathogenesis of numerous neurological disorders (Valenti et al., 2014). Increased ROS 
formation is especially problematic because the resultant oxidative stress leads to tissue 
damage and cell death (el Bekay et al., 2007). Neuronal tissues are particularly 
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susceptible to ROS damage due to their high oxidative demand (el Bekay et al., 2007). 
Indeed, enhancements in ROS production, lipid peroxidation, and protein oxidation were 
observed in the brains of Fmr1 KO mice (el Bekay et al., 2007). Additionally, chronic 
pharmacological treatment with an antioxidant/ free radical scavenger, a-tocopherol, 
reversed the oxidative damage phenotypes in the Fmr1 KO mice (de Diego-Otero et al., 
2009).  
Taking the studies of oxidative damage in the Fmr1 KO mice along with the 
findings that I presented in Chapter 3, it is evident that a more in depth assessment of 
ROS levels and the repercussions thereof in FXS models would be highly informative. 
The assessment of ROS levels in the dfmr1 mutants is especially enticing because 
Drosophila pre-mRNA adenosine deaminase (dADAR), which is known to interact 
genetically and biochemically with dFMR1, has been shown to regulate ROS metabolism 
in the CNS (Bhogal et al., 2011; Chen et al., 2004). Fortunately, there are several well 
established methods to directly measure ROS levels in Drosophila (Owusu-Ansah et al., 
2008; Pavelescu, 2015). Further, indirect measures such as the abundance of lipid 
peroxidation and protein oxidation can also be used as a proxy for ROS levels. Hopefully, 
these tools will be used to determine whether aberrant ROS dynamics are conserved 
between murine and Drosophila FXS models. If excess levels of ROS are detected in the 
brain and/or periphery of the dfmr1 mutant flies, it would be interesting to determine 
whether genetic and/or pharmacological manipulations that normalize ROS levels are 
sufficient to rescue the observed metabolic, mitochondrial, and/or behavioral and 
cognitive phenotypes exhibited by the dfmr1 mutants.  
  
111 
	
Evaluate the transcriptome of peripheral tissues in models of FXS  
 To date, high-throughput approaches have only been used to identify putative 
targets of FMRP in neuronal tissues (Brown et al., 2001; Darnell et al., 2011; Tabet et al., 
2016a). Consequently, there is a large gap in our understanding of FMRP function 
outside the context of the brain. In light of the systemic nature of FXS, the field would 
benefit immensely from the application of transcriptomics technology to the study of 
peripheral tissues in FXS models. Analysis of the liver transcriptome in Fmr1 KO mice 
and/or the transcriptome of the abdominal fat body of dfmr1 mutant flies would provide 
key insights into the mechanisms by which dFMRP regulates peripheral metabolism. 
Similarly, transcriptomics analysis of mitochondrial preparations from FXS models 
would reveal clues about the mechanistic underpinnings of the observed mitochondrial 
dysfunction. Once putative targets have been identified and verified, it will be possible to 
pinpoint peripheral processes that are affected by the loss of dFMRP. Such information 
can be used to identify direct targets of dFMRP as well as indirect effects of the loss of 
dFMRP.  
 
Concluding Remarks 
Ultimately, it is an exciting time in FXS research because the field is at an 
ideological crossroads. The etiology of FXS and the hallmark symptoms observed in 
human patients are well characterized. However, there is still much to be learned 
regarding the molecular underpinnings of FXS. Our incomplete understanding of the 
precise mechanisms that contribute to FXS pathogenesis has precluded the identification 
of effective therapeutic approaches to ameliorate the quality of life of affected 
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individuals. The most salient example of this problem is the recent finding from two 
independent clinical trials that pharmacological treatment with metabotropic glutamate 
receptor antagonists failed to provide therapeutic benefit to FXS patients. Moving 
forward, there are several ways in which more stringent preclinical research can improve 
the likelihood of success in clinical settings.  
In this Chapter, I described promising avenues for further exploration that have 
the potential to reveal novel, clinically relevant links between metabolism and behavioral 
and cognitive output. Notably, the identification of metabolic and/or mitochondrial 
disturbances that underlie impairments in behavior and cognition would uncover new 
targets for therapeutic intervention. Such findings have the potential to elucidate 
biomarkers that can be used to help clinicians determine which patients are the best 
candidates for treatment with compounds that alter metabolism. The discovery of 
biomarkers would also provide clinicians with objective, quantitative measures of 
treatment efficacy, as clinical trials are currently limited to subjective assessments. Given 
the heterogeneity of the phenotypes and medical problems found to be associated with 
FXS, it is not realistic to expect a panacea. However, the discovery of ubiquitous 
therapeutic targets that reduce the number of medications that FXS patients must 
consume as well as the identification of relevant biomarkers to assess treatment efficacy 
constitute profound and achievable goals for the field. 
 
  
113 
	
 
 
 
 
APPENDIX A: 
 
 
THE METABOLOMIC PROFILE OF THE DROSOPHILA  
MODEL OF FXS4 
  
																																								 																				
4	This work has been submitted for publication 
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Introduction 
 In the interest of brevity, the complete metabolomics dataset was not presented in 
Chapter 2. Rather, I only showed the respective fold changes of biochemicals that I 
explicitly discussed in Chapter 2. This Appendix contains the complete metabolomics 
dataset that was provided to us by Metabolon, Inc. All commentary about the 
experimental hypothesis, design, results, and discussion can be found in Chapter 2.   
 
Results 
Table A.1. Summary of the fold changes of all the biochemicals profiled in the 
metabolomics study. Welch’s two-sample t-test was used to identify significant 
differences in the metabolite ratios. Boxes shaded in green indicate a significant 
difference (p£0.05) in which the metabolite ratio was less than 1.00. Boxes shaded in red 
indicate a significant difference (p£0.05) in which the metabolite ratio was more than 
1.00. The light green boxes denote metabolites that narrowly missed the statistical cutoff 
for significance (0.05<p<0.10) in which the metabolite ratio was less than 1.00. The light 
red boxes signify metabolites that narrowly missed the statistical cutoff for significance 
(0.05<p<0.10) in which the metabolite ratio was greater than 1.00. Boxes without color 
represent mean values that were not significantly different. * denotes a compound that 
has not been confirmed based on a standard but is of known identity. 
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APPENDIX B: 
 
 
EXPRESSION OF THE DROSOPHILA FRAGILE X MENTAL RETARDATION 
PROTEIN IN THE ABDOMINAL FAT BODY IS NOT SUFFICIENT TO 
NORMALIZE TRIGLYCERIDE LEVELS IN THE  
DROSOPHILA MODEL OF FXS 
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Rationale 
 The abdominal fat body is the primary site of lipid storage in Drosophila (Arrese 
and Soulages, 2010). Studies in ex vivo coculture of dissected brains and larval fat bodies 
revealed that the dietary status of the fat body is relayed to the brain by way of a humoral 
“remote control” signal to modulate insulin release (Géminard et al., 2009). Remarkably, 
the dietary status of the fat body was found to override that of the brain such that the 
incubation of starved brains with fed fat body explants triggered the secretion of 
Drosophila insulin like peptides (dILPS) (Géminard et al., 2009). Notably, this model 
raises the possibility that dfmr1 is required in the fat body to modulate the levels of stored 
triglycerides. 
Moreover, it has been shown that the circadian clock in the central nervous 
system and the circadian clock in the abdominal fat body work in opposition to regulate 
triglyceride levels (Xu et al., 2008). Our laboratory has demonstrated that the circadian 
clock in the CNS is intact in the dfmr1 mutant flies (Dockendorff et al., 2002). However, 
results in murine models of FXS suggest that the function of the peripheral clock in the 
liver is compromised in Fmr1/Fxr2 double knockout mice. Thus, perturbation of the 
antagonistic relationship between the clock in the CNS and the clock in the fat body 
could also explain the observed reduction in triglyceride levels in the dfmr1 mutant flies. 
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Hypothesis 
It is plausible that the communication between the CNS and the peripheral 
metabolic organs, either by a neuroendocrine signal and/or by circadian cross-talk, is 
disrupted in the dfmr1 mutant flies. Thus, I anticipated that reintroduction of dfmr1 into 
the abdominal fat body would ameliorate communication between the CNS and the 
periphery and thereby restore triglycerides to wild-type levels. 
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Results 
 
Figure B.1 Restoration of dfmr1 in the abdominal fat body alone is insufficient to 
rescue triglycerides to wild-type levels. Triglyceride levels were measured in 5-7 day 
old male flies of different genotypes. The resultant values were then normalized to 
protein content. Fly heads were removed prior to homogenization. Sample number (N) 
per genotype: to-Gal4; dfmr1 = 16, UAS-dfmr1>to-Gal4; dfmr1 = 16, UAS-dfmr1; dfmr1 
= 23, UAS-dfmr1; + = 14. Each sample contained one fly body. Two-way ANOVA found 
the interaction between genotype and triglyceride levels to be extremely significant 
(p>0.0001). Post hoc Tukey’s multiple comparison test results indicated that restoration 
of dfmr1 in the abdominal fat body alone was not sufficient to rescue triglyceride levels. 
Data shown represent the cumulative results of 3 independent experiments. Values 
represent mean ± SEM. ****p<0.0001 
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Discussion 
 Expression of dfmr1 in the abdominal fat body in a genetic background that is 
otherwise dfmr1 mutant is not sufficient to rescue the observed depletion in triglyceride 
levels. Considering that 90% of lipids are stored in the abdominal fat body as 
triglycerides, this data indicates that perhaps dfmr1 operates in a cell-non-autonomous 
manner to regulate lipid metabolism. Moreover, my results suggest that if the circadian 
clock in the abdominal fat body is disrupted, either the reintroduction of dfmr1 alone is 
insufficient to restore peripheral clock function and/or another mechanism underlies the 
observed defect in triglyceride storage. 
 
Materials and Methods 
Fly genetics and husbandry 
Fly strains that contain the dfmr13 allele and WT rescue transgene are described in 
Dockendorff et al., (Dockendorff et al., 2002). These flies were outcrossed to 
w1118(iso31Bw-) flies as described in Monyak et al., (Monyak et al., 2016). The takeout-
Gal4 strain was generously contributed by Renske Erion and Amita Sehgal. I 
subsequently outcrossed the takeout-Gal4 strain from the Sehgal laboratory to 
w1118(iso31Bw-) flies for six generations. Next, I crossed the dfmr13 allele into the 
isogenic stock. All fly strains were cultured on a standard cornmeal-molasses medium 
and maintained in the presence of stringent 12 hours light: 12 hours dark (LD) cycles at 
25°C. 
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Triglyceride Measurement 
Triglyceride levels were measured as described in DiAngelo and Birnbaum (DiAngelo 
and Birnbaum, 2009). Briefly, individual 5 to 7 day old adult male flies were collected on 
dry ice. Fly heads were removed prior to homogenization, as the presence of eye pigment 
can interfere with accurate absorbance measurements(Tennessen et al., 2014). The 
decapitated fly bodies were then homogenized in lysis buffer that contained 140mM 
NaCl, 50mM Tris-HCL, pH 7.4, 20% Triton X-100, and 1X protease inhibitors (Roche, 
Indianapolis, IN). The homogenate was then centrifuged at 15871 x g for 10 minutes at 
4C°. Triglyceride concentrations were determined in triplicate with the Triglyceride 
LiquiColor kit (Stanbio Laboratory, Boerne, TX). The protein concentration of each 
sample was measured with the Pierceâ BCA Protein Assay Kit (Thermo Scientific, 
Rockford, IL). The triglyceride concentration of each sample was then normalized to its 
respective protein content. 
Statistics 
For the metabolomics data, standard statistical analyses were performed in ArrayStudio 
on log transformed data. Unpaired t-tests were used to evaluate pairwise comparisons. 
Multiple comparisons were investigated using one-way analysis of variance (ANOVA) 
with post hoc Tukey tests.  
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Fly Food—Full Recipe from Jongens Lab 
 
1) Start heating 2000 mL H2O and add 25.94 g agar  
 
2) Add 510 mL H2O to a beaker and mix in 40 g yeast and 160 g cornmeal 
 
3) When water begins to boil, turn heat down to 1 and add yeast/cornmeal mixture 
slowly.  Cover pot with tinfoil and let mix for 15 mins. 
 
4) Mix 157.6 mL molasses and 250 mL H2O in a graduated cylinder and add into pot.  
Add 70 mL H2O.  Let mix for 30 mins. 
 
5) Add .8 mL phosphoric acid, 7 mL propionic acid and 25.2 mL 25% tegosept.  Mix 
for 3 mins then dispense.   
 
 
 
To make Tegosept: Add 50g of tegosept into 200mL EtOH 
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Glycogen Measurement 
Courtesy of Michelle Bland from the Birnbaum Laboratory  
 
Solutions & reagents needed: 
0.1 M NaOH 
0.2 M acetate, pH 4.8 
Amyloglucosidase (AMG), 5 mg/mL in 0.2 M acetate, pH 4.8 (Sigma A7420-25MG) 
Amplex Red Glucose/Glucose Oxidase Assay kit (Invitrogen A22189) 
Bicinchoninic Acid Protein Assay kit, Peirce 
Kontes pestle and tubes 
Tissue disruption 
1. homogenize flies (4 flies / tube) in 200 µL 0.1 M NaOH using Kontes pestle 
2. centrifuge 13,000 rpm, 10 min, 4˚C 
3. transfer supernatant to new tube 
 
Glycogen assay 
1. Set up two sets of reactions: 
 A) 20 µL lysate + 100 µL 0.2 M acetate, pH 4.8 
B) 20 µL lysate +  80 µL 0.2 M acetate, pH 4.8 + 20 µL 5 mg/mL AMG 
2. Incubate reactions for 2 hours at 37˚C 
3. Dilute incubated samples 1:3 in 1X reaction buffer from Amplex Red Kit. 
4. Pipette 40 µL each of standards (see below) and 40 µL diluted unknowns into each 
well.   
    Perform assay in triplicate.   
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Standards (enough for two plates): 
concentration  500 µM glucose reaction buffer   
150 µM  90 µL   210 µL 
100    60   240 
  80   48   252 
60   36   264 
40   24   276 
20   12   288 
10    6   294 
0    0    300 
 
5. Prepare reaction mix (40 µL for each well). 
   85 µL  10 mM Amplex Red 
 170 µL 10 U/mL HRP 
 170 µL 100 U/mL glucose oxidase 
 8.075 mL  reaction buffer 
 
6. Add 40 µL reaction mix to each well 
7. Incubate 30 minutes, room temperature, protected from light 
8. Read in a plate reader at 570 nm 
 
Protein Assay 
Measure protein in 20 µL of original lysate using the BCA assay kit. 
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Calculations 
Glucose level in –AMG samples = free glucose 
Glucose level in +AMG samples = free glucose + glycogen 
 
1. Subtract –AMG glucose from +AMG glucose to get glycogen level 
2. Calculate amount of free glucose and glycogen in 1 µL of the orginal lysate (see 
below) 
3. Calculate amount of protein in 1 µL of the original lysate 
4. Normalize free glucose and glycogen levels to total protein. 
5. Statistics. 
 
As the assay in this protocol is described: 
20 µL lysate + 100 µL acetate (+/- AMG) 
40 µL incubated lysate (equivalent to 6.7 µL lysate) + 80 µL reaction buffer 
40 µL diluted, incubated lysate (equivalent to 2.2 µL lysate) + 40 µL reaction mix 
 
Protein = 2-5 µL of original lysate 
 
 
 
To note: 
The Amplex Red assay is saturated at high levels of glucose, so you may need to create a 
different standard curve or dilute samples more than 1:3. 
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Triglyceride assay – Drosophila larvae or adults 
Courtesy of Michelle Bland from the Birnbaum Laboratory  
 
Solutions & reagents needed: 
Stanbio Triglyceride Liquicolor Kit (Cat no. 2100-430) 
Bicinchoninic Acid Protein Assay kit, Peirce 
 
Triglyceride lysis buffer: 
recipe     10 mL 
 140 mM NaCl    280 µL  5 M NaCl 
 50 mM Tris-HCl, pH 7.4  500 µL  1 M Tris-HCl, pH 7.4 
 20% Triton X-100       10 µL  Triton X-100 
 1X Protease inhibitors  400 µL  25X protease inhibitors 
      8.81 mL H2O 
 
Tissue disruption 
1.  Prepare fresh triglyceride lysis buffer.  Chill on ice. 
2.  Add 150 µL lysis buffer to each sample.   
3.  Sonicate each larva/adult 3 times, 10 seconds per time at level 4.5.   Keep samples on 
ice  
     between sonication steps. 
4.  Centrifuge 13,000 rpm, 10 min, 4˚C. 
5.  Transfer supernatant to new tube.  Use directly in assay or freeze at –20˚C. 
 
 
 
 
140 
	
Triglyceride measurement – Stanbio Triglyceride Assay kit. 
1.  Prepare activated triglyceride reagent.  Let sit at room temperature until ready for use.  
Each  
     well requires 90 µL.  10 mL of activated reagent is sufficient for a whole 96-well 
plate. 
 
 10 mL activated triglyceride reagent: 
 100 µL yellow activator reagent (from eyedropper bottle). 
 9.9 mL triglyceride reagent 
 
2.  Prepare triglyceride standards in Eppendorf tubes. 
 
Concentration  1X PBS Triglyceride std (2mg/mL stock) 
    0 µg/mL  40 µL   0 µL 
   50   39   1 
  100   38   2 
  200   36   4 
  400   32   8 
  800   24  16 
1600    8  32 
 
3.  Pipette 10 µL of each standard in triplicate as shown in the template (next page). 
4.  Add 10-15 µL of each unknown in triplicate as shown in the template. 
5.  Add 90 µL of activated triglyceride reagent to each well. 
6.  Incubate at 37˚C for 5 min. 
7.  Read plate at 500 nm. 
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Protein measurement – Pierce BCA kit. 
Triglyceride lysis buffer interferes with the assay to a small degree, so add triglyceride 
lysis buffer to each standard in the same volume used for each unknown. 
 
Typically use 10 or 15 µL lysate per sample. 
 
 
Data analysis 
1.  Divide protein and triglyceride concentrations by volume used for each sample to get 
µg/µL. 
2.  Divide triglyceride concentration by protein concentration. 
3.  Statistics. 
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NAD+/NADH Quantification Colorimetric Kit (#K337-100) 
 
Reagent reconstitution: 
• Warm Extraction and Cycling Buffers to RT (store at -4°C or -20°C) 
• Add 220µL NAD Cycling Buffer to NAD Cycling Enzyme Mix. Aliquot volume needed 
for each experiment (3 aliquots of 58 µL, store at -80°C) 
• Add 1.2mL ddH2O to Developer. Pipette to mix-do not vortex (store at -20°C protected 
from light)  
• Add 200µL DMSO to Standard (store at -20°C) 
 
Sample preparation: 
• Pool 10 decapitated adult male flies 
• Homogenize in 400µL of Extraction Buffer  
• Vortex for 10 seconds 
• Centrifuge at 14000 rpm for 5 minutes 
• Transfer supernatant to a new tube  
• Aliquot 200µL of homogenate into a new tube and heat to 60C for 30 minutes to 
decompose NAD. Cool immediately on ice and spin if precipitate occurs. 
• Load 50µL of the original and heated samples in duplicate 
 
Standard curve preparation: 
• Dilute 10µL of NADH standard in 990µL Extraction Buffer 
• Load the following reagents in duplicate 
 
NADH Standard(µL) Extraction Buffer(µL) 
0 100 
4 96 
8 92 
12 88 
16 84 
20 80 
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Plate Procedure: 
• Prepare Reaction Mix (98µL Cycling Buffer + 2µL Cycling Enzyme Mix) 
• Add 100µL Reaction Mix into each well 
• Incubate for 5 minutes on shaker at room temperature 
• Add 10µL NADH Developer into each well 
• Read plate at 450nm, cycle at room temperature for 1-4 hours at room temperature (can 
read multiple times) 
• Stop reaction with 10µL Stop Solution. Color will be stable for 48 hours. 
 
NAD/NADH ratio: NADtotal-NADH 
   NADH 
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Mitochondrial Enrichment Protocol 
Courtesy of Atif Towheed from the Wallace Laboratory  
1. Isolate 40-50 thoraces per genotype into a 1.5ml microcentrifuge tube with 100 µl 
of chilled mitochondrial isolation medium (MIM: 250mM Sucrose, 10mM Tris-
HCl pH 7.4, 0.15 mM MgCl2) 
 
2. Add protease inhibitor mix (1:100)  
 
 
3. Homogenize gently using a blue plastic pestle homogenizer 
 
4. Add 500 ul of MIM w/ protease inhibitor mix (1:100) 
 
 
5. Continue to homogenize with the pestle 
 
6. Centrifuge at 500 x g for 5 min at 4˚C.  
 
 
7. Remove supernatant from debris and repeat Step 6. 
 
8. Collect the supernatant in a fresh tube  
 
 
9. Centrifuge the supernatant at 5000 x g for 5 min at 4˚C. A pellet will form on the 
bottom of the tube that contains the mitochondrial fraction.  
 
10. Wash the pellet with 500 ul of MIM w/ protease inhibitor mix (1:100), 
resuspending the pellet gently with a pipette.  
 
 
11. Centrifuge at 5000 x g for 5 min at 4˚ C. Resuspend the pellet in MIM or assay 
buffer (for example MiRO5 for O2k).  
 
 
 
Reference: Modulation of Longevity and Tissue Homeostasis by the Drosophila PGC-1 
Homolog. Michael Rera and David Walker et. al., Cell Metabolism 2011 
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Western Blot Protocol using Invitrogen System 
 
In Advance: 
1)    Add 12.5µL 200mM Na3VO4 to 25mL of filter sterilized extraction buffer 
 
 
Protein Extraction: 
0)    Turn heat block to 100°C and set centrifuge to 4°C. 
 
1)    Complete extraction buffer by adding 10µL 100X protease inhibitor cocktail (PIC), 
1µL 1M DTT and 10µL .5M EGTA to 1mL of premade extraction buffer with Na3VO4. 
 
2)    Freeze flies on dry ice, and remove heads by shaking tube.  Transfer fly bodies/heads 
into petri dish (on dry ice) and transfer fly heads into frozen blue 1.5mL tube (suitable for 
homogenizer). 
 
3)    Add 2µL of extraction buffer for each fly head (20µL for 10 heads, etc.) and 
homogenize.  Keep tubes on ice once extraction buffer is added.  Spin tubes for 30 
seconds at 13,000 rpm in 4°C centrifuge. 
 
4)    Remove supernatant and save on ice.  Add an additional 2µL/fly head of extraction 
buffer to tube with pellet and rehomogenize.  Spin these tubes and saved supernatant 
tubes for 5 minutes at 13,000 rpm in 4°C centrifuge.  Combine supernatant in fresh tube. 
 
5)    Make a master mix of 4X NuPage LDS sample buffer (blue) and 10X NuPage 
reducing agent (in fridge). 
 -Add 7.5µL 4X LDS Buffer and 3µL 10X reducing agent per sample (for final 
volume of 30µL) 
 -Add 10.5µL master mix to individual tubes 
 
6)     Add 19.5µL supernatant to master mix, mix and spin down quickly, then boil at 
100°C  for 5 minutes.  Allow samples to cool then store on ice while setting up gel. 
 *Make sure truly boiled or you could get wiggly bands* 
 
 
Running Gel: 
1)    Make 1X MOPS Buffer  
 40mL 20X MOPS 
 Fill to 800mL with ddH2O 
 
2)    Unwrap precast gel, remove white tape at bottom and gently remove comb.  Rinse 
with ddH2O, then put in gel box with writing on gel facing forward (large plate should be 
facing outside of gel box and small plate should be facing inside).   
 
3)    Fill gel box with 1X MOPS buffer, then add 500µL NuPage antioxidant to inside 
chamber (space between two gels or gel and mock gel). 
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4)    Quick spin samples down, then load 25µL of supernatant (don’t disturb pellet).  
Load samples from right to left since transfer will put them in reverse order.  Load 5µL 
ladder as well. 
 
5)    Run gel at 200V for 1 hour (you can increase time by decreasing volts). 
Transfer: 
1)    Make 1X Transfer Buffer 
 30mL 20X Transfer Buffer 
 60mL methanol 
 600µL NuPage Antioxidant 
 Fill to 600mL 
 
2)   Fill 3 containers with methanol, ddH2O and 1X Transfer Buffer and soak P-
immobilon membrane: 
 15 seconds in methanol 
 2 mins in ddH2O 
 5+ mins in 1X Transfer Buffer  
 
3)    Soak 6 blotting pads and 2 pieces of filter paper (cut to size of gel) in 1X Transfer 
Buffer.  Flip and squeeze to remove air bubbles. 
 
4)    Once gel has finished running, remove it from gel box and place upside down on 
piece of saran wrap (so smaller piece of plastic is facing upwards).   
 
5)    Remove plastic covering gel and cut off wells, taking care to push them away from 
gel so they don’t interfere with transfer.  Then put soaked piece of filter paper over gel 
and smooth down to remove air bubbles. 
 
6)    Flip gel over and remove top piece of plastic by placing knife through the slot and 
gently pushing gel off.  Once plate is removed, cut off foot of gel, and gently place 
membrane on gel (don’t touch with hands) and smooth down).  Place soaked filter paper 
on top of membrane and smooth down. 
 
7)    Put three soaked blotting pads in transfer box.  Move gel/membrane/filter paper 
stack on top without flipping it over.  Put two soaked blotting pads on top and put 
transfer box into new clean gel box while squeezing together.  Do not stop squeezing 
until transfer box is firmly in place. 
 
8)    Add 1X Transfer Buffer to inside of transfer box until everything is covered.  Fill the 
outside of gel box with ddH2O. 
 
9) Add gel box lid and transfer at 45V for 1 hour (this time/voltage cannot be changed). 
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Staining Day 1: 
1)    Remove membrane from box and block in 5% milk (in TBS-T--.1%Tween) for 1 
hour at room temperature. 
 
2)    Wash in 1° antibody overnight at 4°C on rocker. 
 
 
Staining Day 2: 
1)    Wash membrane in 1X TBS-T (.1% Tween) for 10 mins x 4 
 
2)    Incubate at room temperature in 2° antibody for 2-3 hours 
 
3)    Wash membrane in 1X TBS-T for 10 mins x 4. 
 
4)    Mix equal amounts of the ECL substrate chemicals together and incubate on blot for 
5 mins. (Use West Pico kit for easy to detect proteins and Lumi Light kit for more 
sensitive detection).   
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